

EUROPEAN PATENT OFFICE
U.S. PATENT AND TRADEMARK OFFICE

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

The following classification changes will be effected by this Notice of Changes:

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
SCHEME:		
Symbols Deleted:	C07K	16/1002
	C07K	16/1003
	C07K	16/1009
	C07K	16/1018
	C07K	16/1027
	C07K	16/1036
	C07K	16/1045
	C07K	16/1054
	C07K	16/1063
	C07K	16/1072
	C07K	16/1081
	C07K	16/109
Symbols New:	C07K	16/102
	C07K	16/104
	C07K	16/106
	C07K	16/108
	C07K	16/11
	C07K	16/112
	C07K	16/114
	C07K	16/1143
	C07K	16/1145
	C07K	16/1147
	C07K	16/116
	C07K	16/118
Titles Changed:	C07K	16/00
	C07K	16/081
	C07K	16/082
	C07K	16/084
	C07K	16/085
	C07K	16/087
	C07K	16/10
	C07K	16/1203
	C07K	16/121
	C07K	16/1214
	C07K	16/1217
	C07K	16/1218
	C07K	16/1228
	C07K	16/1232
	C07K	16/1235
	C07K	16/1246

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

<u>Action</u>	<u>Subclass</u>	<u>Group(s)</u>
	C07K	16/126
	C07K	16/1267
	C07K	16/1271
	C07K	16/1275
	C07K	16/1278
	C07K	16/1282
	C07K	16/1289
Notes Modified	C07K	16/00
DEFINITIONS:		
Definitions Modified:	C07K	16/00

No other subclasses/groups are impacted by this Notice of Changes.

This Notice of Changes includes the following *[Check the ones included]:*

1. CLASSIFICATION SCHEME CHANGES

- ☒ A. New, Modified or Deleted Group(s)
- ☐ B. New, Modified or Deleted Warning(s)
- ☒ C. New, Modified or Deleted Note(s)
- ☐ D. New, Modified or Deleted Guidance Heading(s)

2. DEFINITIONS

- ☒ A. New or Modified Definitions (Full definition template)
- ☐ B. Modified or Deleted Definitions (Definitions Quick Fix)

3. ☒ REVISION CONCORDANCE LIST (RCL)

4. ☒ CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)

5. ☐ CHANGES TO THE CROSS-REFERENCE LIST (CRL)

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

1. CLASSIFICATION SCHEME CHANGES

A. New, Modified or Deleted Group(s)

SUBCLASS C07K - PEPTIDES

<u>Type*</u>	<u>Symbol</u>	<u>Indent Level</u> <u>Number of dots</u> <u>(e.g. 0, 1, 2)</u>	<u>Title</u> “CPC only” text should normally be enclosed in {curly brackets}**	<u>Transferred to[#]</u>
M	C07K16/00	0	Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies	
U	C07K16/08	1	against material from viruses	
M	C07K16/081	2	DNA viruses	
M	C07K16/082	3	Hepadnaviridae (F), e.g. hepatitis B virus	
M	C07K16/084	3	Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus	
M	C07K16/085	3	Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus	
M	C07K16/087	4	Herpes simplex virus	
M	C07K16/10	2	RNA viruses	
D	C07K16/1002	3	{Coronaviridae}	<administrative transfer to C07K16/102>
D	C07K16/1003	4	{Severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2 or Covid-19]}	<administrative transfer to C07K16/104>
D	C07K16/1009	3	{Picornaviridae, e.g. hepatitis A virus}	<administrative transfer to C07K16/106>
D	C07K16/1018	3	{Orthomyxoviridae, e.g. influenza virus}	<administrative transfer to C07K16/108>
N	C07K16/102	3	Coronaviridae (F)	
D	C07K16/1027	3	{Paramyxoviridae, e.g. respiratory syncytial virus}	<administrative transfer to C07K16/11>
D	C07K16/1036	3	{Retroviridae, e.g. leukemia viruses}	<administrative transfer to C07K16/112>
N	C07K16/104	4	Severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]	
D	C07K16/1045	4	{Lentiviridae, e.g. HIV, FIV, SIV}	<administrative transfer to C07K16/114>
D	C07K16/1054	5	{gag-pol, e.g. p17, p24}	<administrative transfer to C07K16/1143>

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

N	C07K16/106	3	Picornaviridae (F), e.g. hepatitis A virus	
D	C07K16/1063	5	{env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site}	<administrative transfer to C07K16/1145>
D	C07K16/1072	5	{Regulatory proteins, e.g. tat, rev, vpt}	<administrative transfer to C07K16/1147>
N	C07K16/108	3	Orthomyxoviridae (F), e.g. influenza virus	
D	C07K16/1081	3	{Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus}	<administrative transfer to C07K16/116>
D	C07K16/109	4	{Hepatitis C virus; Hepatitis G virus}	<administrative transfer to C07K16/118>
N	C07K16/11	3	Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]	
N	C07K16/112	3	Retroviridae (F), e.g. leukemia viruses	
N	C07K16/114	4	Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]	
N	C07K16/1143	5	{Gag-pol proteins, e.g. p17 or p24}	
N	C07K16/1145	5	{Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}	
N	C07K16/1147	5	{Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]}	
N	C07K16/116	3	Togaviridae (F); Matonaviridae (F); Flaviviridae (F)	
N	C07K16/118	4	Hepatitis C virus; GB virus C [GBV-C]	
U	C07K16/12	1	against material from bacteria	
M	C07K16/1203	2	Gram-negative bacteria	
M	C07K16/121	3	Helicobacter (G); Campylobacter (G)	
M	C07K16/1214	3	Pseudomonadaceae (F)	
M	C07K16/1217	3	Neisseriaceae (F)	
M	C07K16/1218	3	Acinetobacter (G)	
M	C07K16/1228	3	Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)	

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

M	C07K16/1232	4	Escherichia (G)	
M	C07K16/1235	4	Salmonella (G)	
M	C07K16/1246	3	Rickettsiales (O)	
M	C07K16/126	3	Legionella (G)	
M	C07K16/1267	2	Gram-positive bacteria	
M	C07K16/1271	3	Micrococccaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)	
M	C07K16/1275	3	Streptococcus (G)	
M	C07K16/1278	3	Bacillus (G)	
M	C07K16/1282	3	Clostridium (G)	
M	C07K16/1289	3	Mycobacteriaceae (F)	

*N = new entries where reclassification into entries is involved; C = entries with modified file scope where reclassification of documents from the entries is involved; Q = new entries which are firstly populated with documents via administrative transfers from deleted (D) entries. Afterwards, the transferred documents into the Q entry will either stay or be moved to more appropriate entries, as determined by intellectual reclassification; T = existing entries with enlarged file scope, which receive documents from C or D entries, e.g. when a limiting reference is removed from the entry title; M = entries with no change to the file scope (no reclassification); D = deleted entries; F = frozen entries will be deleted once reclassification of documents from the entries is completed; U = entries that are unchanged.

NOTES:

- **No {curly brackets} are used for titles in CPC only subclasses, e.g. C12Y, A23Y; 2000 series symbol titles of groups found at the end of schemes (orthogonal codes); or the Y section titles. The {curly brackets} are used for 2000 series symbol titles found interspersed throughout the main trunk schemes (breakdown codes).
- U groups: it is obligatory to display the required “anchor” symbol (U group), i.e. the entry immediately preceding a new group or an array of new groups to be created (in case new groups are not clearly subgroups of C-type groups). Always include the symbol, indent level and title of the U group in the table above.
- All entry types should be included in the scheme changes table above for better understanding of the overall scheme change picture. Symbol, indent level, and title are required for all types.
- “Transferred to” column must be completed for all C, D, F, and Q type entries. F groups will be deleted once reclassification is completed.
- When multiple symbols are included in the “Transferred to” column, avoid using ranges of symbols in order to be as precise as possible.
- For administrative transfer of documents, the following text should be used: “<administrative transfer to XX>”, “<administrative transfer to XX and YY simultaneously>”, or “<administrative transfer to XX, YY, ...and ZZ simultaneously>” when administrative transfer of the same documents is to more than one place.
- Administrative transfer to main trunk groups is assumed to be the source allocation type, unless otherwise indicated.
- Administrative transfer to 2000/Y series groups is assumed to be “additional information”.

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

- If needed, instructions for allocation type should be indicated within the angle brackets using the abbreviations “ADD” or “INV”: <administrative transfer to XX ADD>, <administrative transfer to XX INV>, or <administrative transfer to XX ADD, YY INV, ... and ZZ ADD simultaneously>.
- In certain situations, the “D” entries of 2000-series or Y-series groups may not require a destination (“Transferred to”) symbol, however it is required to specify “<no transfer>” in the “Transferred to” column for such cases.
- For finalization projects, the deleted “F” symbols should have <no transfer> in the “Transferred to” column.
- For more details about the types of scheme change, see CPC Guide.

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

C. New, Modified or Deleted Note(s)**SUBCLASS C07K - PEPTIDES**

<u>Type*</u>	<u>Location</u>	<u>Old Note</u>	<u>New/Modified Note</u>
M	C07K16/00	1. Documents characterised by the technical aspects of the construction of an antibody or fragment thereof, should be classified in C07K16/00 - C07K16/065 or C07K16/46 - C07K16/468 2. Documents not characterised by the technical aspects of the construction of an antibody or fragment thereof, should be classified only according to their specificity, where necessary accompanied by one or more appropriate indexing codes	1. In this main group, where appropriate, after the virus or bacteria terminology, the indication of the order (O), family (F) or genus (G) is given in parentheses. 2. {Documents characterised by the technical aspects of the construction of an antibody or fragment thereof, should be classified in groups C07K 16/00 - C07K 16/065 or groups C07K 16/46 - C07K 16/468.} 3. {Documents not characterised by the technical aspects of the construction of an antibody or fragment thereof, should be classified only according to their specificity, where necessary accompanied by one or more appropriate indexing codes.}

*N = new note, M = modified note, D = deleted note

NOTE: The "Location" column only requires the symbol PRIOR to the location of the note. No further directions such as "before" or "after" are required.

DATE: JANUARY 1, 2026

PROJECT RP12806

2. A. DEFINITIONS (modified)

C07K16/00

Replace: The existing Definition statement with the following updated statement.

Definition statement

This place covers:

Antibodies, immunoglobulins and proteins derived therefrom that bind a specific antigen and have as minimal structural features an immunoglobulin framework and three CDRs (i.e. a variable domain). In addition, antibody mimetics and scaffolds that bind a specific antigen. Where appropriate, the term antibody as used in these definitions also encompasses said antigen-binding mimetics and scaffolds. The terms antibodies and immunoglobulins are often used interchangeably.

This main group covers the following aspects of antibodies:

Structure;

Production;

Specificity;

Cells producing the antibody, e.g. hybridomas producing a monoclonal antibody;

DNA/RNA encoding an antibody:

- Therapeutic and prophylactic use
- Diagnostic use and use for detection
- Fusion proteins comprising at least the antigen-binding region of an antibody;

Antibody mimetics and scaffolds.

References

Delete: The entire Limiting references section.

Delete: The entire Application-oriented references section.

DATE: JANUARY 1, 2026

PROJECT RP12806

Replace: The existing Informative references table with the following updated table.

Informative references

Attention is drawn to the following places, which may be of interest for search:

General methods for the preparation of peptides	C07K 1/00
Peptides having more than 20 amino acids	C07K 14/00
Medicinal preparations containing blood products	A61K 35/14
Medicinal preparations containing peptides	A61K 38/00
Medicinal preparations containing antigens	A61K 39/00
Medicinal preparations comprising a mixture of an antibody and a non-antibody	A61K 39/395
Stabilisation of medicinal preparations comprising antibodies	A61K 39/39591
Mixtures of active ingredients without chemical characterisation	A61K 45/06
Medicinal preparations comprising immunoconjugates	A61K 47/68
Gene therapy	A61K 48/00
Antibodies containing fluorescent labels for use in detection in vivo	A61K 49/0058
Antibodies containing NMR labels for use in detection in vivo	A61K 49/16
Antibodies containing radioactive substances for use in therapy or detection in vivo	A61K 51/10
Antibodies with enzymatic activity	C12N 9/0002
Immunoassay; Biospecific binding assay	G01N 33/53

DATE: JANUARY 1, 2026

PROJECT RP12806

Replace: The existing Special rules text with the following updated text.

Special rules of classification

At least one group and indexing code(s) are both mandatory for relevant and sufficiently disclosed aspects, e.g. for aspects actually disclosed in examples and not just casually claimed or generally referred to in the description.

With regard to the specificity of an antibody for an antigen, the last place rule does not apply.

- (1) Antibody and/or fragments or derivatives thereof, i.e. the product per se. Emphasis is on the antigen specificity of the antibody.

Note: If an antigen that under normal/benign conditions justifies a group for the specifically binding antibody in group ranges [C07K 16/08](#) - [C07K 16/28](#) and [C07K 16/34](#) - [C07K 16/44](#) is disclosed to be (over)expressed under malignant conditions (e.g. in or on a tumor cell), then an additional antibody group in [C07K 16/30](#) - [C07K 16/32](#) (i.e. antibodies against tumor, respectively oncogene antigens) range should be given.

- (2) Antibody or fragments or derivatives thereof. Emphasis is on a new technique for the construction of the immunoglobulin molecule or derivative thereof.

Group [C07K 16/00](#) (general) or group [C07K 16/005](#) (phage display).

Optionally a group in [C07K 16/00](#) (for the specificity, if in an example).

- (3) DNA/RNA encoding an antibody or a fragment thereof.

A group in [C07K 16/00](#) (for the specificity).

No indexing code used for the aspect of DNA/RNA.

- (4) Hybridoma producing a monoclonal antibody. Emphasis is on the antigen specificity of the monoclonal antibody.

A group in [C07K 16/00](#) (for the specificity).

No indexing code used for aspect of hybridoma.

- (5) Hybridoma producing a monoclonal antibody. Emphasis is on the technique of producing the hybridoma.

DATE: JANUARY 1, 2026

PROJECT RP12806

A group in [C12N 5/00](#) (for the hybridoma cell), and/or a group in [C12N 15/00](#) (for the hybridoma technique).

Optionally, a group in [C07K 16/00](#) (for the specificity, if there is an example).

(6) Fusion protein of (at least an antigen-binding part of) an antibody + a non-antibody protein. Not to be confused with 'synthetobodies', see further below.

A group in [C07K 16/00](#) (for the specificity of the antibody part).

A group in [C07K 14/00](#) (for the non-antibody part).

Indexing code [C07K 2319/00](#) (fusion protein).

(7) Fusion protein of an Fc-region of an immunoglobulin + a non-antibody protein.

A group in [C07K 14/00](#) (for the non-antibody part).

Indexing code [C07K 2319/30](#) (Fc fused to non-Ig).

(8) Chemical conjugate of (at least an antigen-binding part of) an antibody + a toxin or drug.

A group in [C07K 16/00](#) (for the specificity) and

A group in [A61K 47/68](#) or its subgroups thereof (if the antibody contains a drug or toxin for use in therapy in vivo), and/or

A group in [A61K 51/10](#) or its subgroups thereof (if the antibody contains a radioactive substance for use in therapy in vivo).

(9) Chemical conjugate of (at least an antigen-binding part of) an antibody + a detectable label.

A group in [C07K 16/00](#) (for the specificity) and

A group in [G01N 33/53](#) or its subgroups thereof (if the antibody is for use in detection in vitro), and/or

A group in [A61K 51/10](#) or its subgroups thereof (if the antibody contains a radioactive substance for use in detection in vivo), and/or

A group in [A61K 49/0058](#) (if the antibody contains a fluorescent label for use in detection in vivo), and/or

DATE: JANUARY 1, 2026

PROJECT RP12806

A group in [A61K 49/16](#) (if the antibody contains a nuclear magnetic resonance label for use in detection in vivo).

(10) Therapeutic use of an antibody or a therapeutic composition comprising an antibody.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [A61K 2039/505](#) (therapeutic use of an antibody, but only if in an in vivo example (this includes pharmacokinetic studies). Note: Because at the date of classification it is not foreseeable how plausible an in vitro assay will be for the assessment of therapeutic effectiveness, in vitro examples, including those that make in vivo therapeutic effectiveness plausible, should be classified in the [C07K 2317/70](#) series, see below), and/or:

- optionally indexing code [A61K 2039/54](#) (route of administration, but only if important), and/or
- optionally indexing code [A61K 2039/545](#) (dose, timing or administration schedule, but only if important), and/or
- optionally indexing code [A61K 2039/57](#) (type of response, e.g. TH1- or TH2-type T cell response).

(11) Therapeutic use of a combination of two or more antibodies or a therapeutic composition comprising two or more antibodies. Said antibodies have an additive or synergistic effect, and the antibodies may be given as a mixture or consecutively. This should not be confused with a mixture of an antibody with a non-antibody, see below:

A group in [C07K 16/00](#) (for the specificity of the first antibody), and

A group in [C07K 16/00](#) (for the specificity of the second antibody), and

Indexing code [A61K 2039/507](#) (therapeutic use of an antibody combination. Note: said code may not only be given for an in vivo example, but also if shown in an in vitro example), and/or

Optionally, indexing code [A61K 2039/54](#) (route of administration, but only if important), and/or

Optionally, indexing code [A61K 2039/545](#) (dose, timing or administration schedule, but only if important), and/or

Optionally, indexing code [A61K 2039/57](#) (type of response, e.g. TH1- or TH2-type response).

DATE: JANUARY 1, 2026

PROJECT RP12806

(12) Therapeutic combinations of antibodies (or fragments thereof) + non-antibody proteins, or compositions comprising these combinations.

A group in [A61K 39/395](#) (or a subgroup thereof), [A61K 2300/00](#); [A61K 39/40](#), [A61K 2300/00](#) or [A61K 39/42](#), [A61K 2300/00](#) as a Combination set [C-Set], and

A group in [A61K 38/00](#) (for the non-antibody protein).

A group in [C07K 16/00](#) (for the specificity).

(13) Therapeutic combinations of antibodies (or fragments thereof) + structurally undefined (e.g. functionally defined) compounds, or compositions comprising these combinations.

A group in [A61K 39/395](#) (or a subgroup thereof), [A61K 2300/00](#); [A61K 39/40](#), [A61K 2300/00](#) or [A61K 39/42](#), [A61K 2300/00](#) as a Combination set [C-Set], and

A group in [A61K 45/06](#) (for the structurally undefined compound).

A group in [C07K 16/00](#) (for the specificity).

(14) Therapeutic combinations of antibodies (or fragments thereof) + blood-derived cells, or compositions comprising these combinations.

A group in [A61K 39/395](#) (or a subgroup thereof), [A61K 2300/00](#); [A61K 39/40](#), [A61K 2300/00](#) or [A61K 39/42](#), [A61K 2300/00](#) as a Combination set [C-Set], and

A group in [A61K 35/14](#) (for the blood-derived cells).

A group in [C07K 16/00](#) (for the specificity).

(15) Diagnostic use of an antibody or a diagnostic composition comprising an antibody. Emphasis is on the antigen specificity, not on the assay technique.

A group in [C07K 16/00](#) (for the specificity).

No indexing code used for aspect of diagnosis.

(16) Diagnostic use of an antibody or a diagnostic composition comprising an antibody. Emphasis is on a new assay technique. The antigen specificity may not be crucial.

A group in [G01N 33/53](#) or its subgroups thereof.

A group in [C07K 16/00](#) (for the specificity, if there is an example).

DATE: JANUARY 1, 2026

PROJECT RP12806

(17) Antibody isolated from eggs. Emphasis is on the isolation technique, not on the antigen specificity.

A group in [C07K 16/02](#) (for the isolation technique from eggs), and

A group in [C07K 16/00](#) (for the specificity, if in an example).

(18) Antibody isolated from eggs. Emphasis is on the antigen specificity, not on the technique of isolation.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/11](#) (antibody isolated from eggs).

(19) Antibody isolated from milk. Emphasis is on the isolation technique, not on the antigen specificity.

A group in [C07K 16/04](#) (for the isolation technique from milk), and

Optionally, a group in [C07K 16/00](#) (for the specificity, if in an example).

(20) Antibody isolated from milk. Emphasis is on the antigen specificity, not on the technique of isolation.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/12](#) (antibody isolated from milk).

(21) Antibody isolated from serum. Emphasis is on the isolation technique, not on the antigen specificity.

A group [C07K 16/06](#) (for the isolation technique from serum), and

Optionally, [C07K 16/00](#) (for the specificity, if in an example).

Note: The term "serum" should be interpreted widely and includes blood and plasma as well. In practice, the subgroup [C07K 16/065](#) is used more often and relates to the purification (e.g. by chromatography, filtration) and fragmentation (e.g. by enzymatic digestion) of the immunoglobulin.

(22) Antibody isolated from plants. Emphasis is on the antigen specificity, not on the technique of isolation.

A group in [C07K 16/00](#) (for the specificity), and

DATE: JANUARY 1, 2026

PROJECT RP12806

Indexing code [C07K 2317/13](#) (antibody isolated from plants).

(23) Antibody characterised by their source of isolation or production. Emphasis is on the protein-expression technique, e.g. to improve yield, purity or glycosylation, e.g. by using specific host-cells, vectors, additives or culture conditions.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/14](#) (source of isolation, production).

(24) Antibody according to its taxonomic origin.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/20](#) (general aspects of origin), and/or

Indexing code [C07K 2317/21](#) (fully primate or fully human, including fully human antibodies produced by transgenic animals, e.g. by Xenomouse®), and/or

Indexing code [C07K 2317/22](#) (fully camelid), and/or

Indexing code [C07K 2317/23](#) (fully avian).

(25) Antibody comprising immunoglobulin-regions, -domains or -residues from more than one species, e.g. chimeric, humanised or veneered antibody. Emphasis is on a new technique of construction, not on the antigen specificity.

A group in [C07K 16/461](#) (for the technique), and

A group in [C07K 16/00](#) (for the specificity, if in an example).

(26) Antibody comprising immunoglobulin-regions, -domains or -residues from more than one species, e.g. chimeric, humanised or veneered antibody. Emphasis is on the antigen specificity, not on the technique of construction.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/24](#) (chimeric, humanised, veneered antibody).

(27) Antibody characterised by general aspects of specificity or valency.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/30](#).

DATE: JANUARY 1, 2026

PROJECT RP12806

(28) Multispecific (i.e. including bispecific) antibody. Emphasis is on a new technique of construction, not on the antigen specificity.

In group [C07K 16/468](#) or its subgroup thereof (for the technique of bispecific antibodies), and

A group in [C07K 16/00](#) (for the first specificity, if in an example), and

A group in [C07K 16/00](#) (for the second specificity, if in an example), and

Optionally, a group in [C07K 16/00](#) (for any additional specificity, if in an example).

(29) Multispecific (i.e. including bispecific) antibody. Emphasis is on the antigen specificity, not on the technique of construction.

A group in [C07K 16/00](#) (for the first specificity), and

A group in [C07K 16/00](#) (for the second specificity), and

Optionally, a group in [C07K 16/00](#) (for any additional specificity, if in an example), and

Indexing code [C07K 2317/31](#) (multispecific antibody).

(30) Antibody specific for a neo-epitope formed by a complex, e.g. antibody-antigen, ligand-receptor. The antibody is monospecific, not bispecific.

A group in [C07K 16/00](#) (for the first component of the complex), and

A group in [C07K 16/00](#) (for the second component of the complex), and

Indexing code [C07K 2317/32](#) (to indicate specificity for the complex).

(31) Antibody characterised by its cross reactivity (e.g. for species or epitope) or lack of cross reactivity.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/33](#) (for the aspect of cross reactivity or explicit lack thereof).

(32) Antibody characterised by its specificity for a well-defined epitope or immunogen, which is either linear and shorter than 20 amino acid residues or conformational and defined by amino acid residues.

A group in [C07K 16/00](#) (for the specificity for the antigen), and

DATE: JANUARY 1, 2026

PROJECT RP12806

Indexing code [C07K 2317/34](#) (linear epitope <20 AA residues or conformational epitope defined by AA residues).

(33) Antibody characterised by its valency and wherein the fact that the molecule is monovalent, bivalent or multivalent is an important feature.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/35](#) (for the aspect of valency, but only if important).

(34) Antibody characterised by its post-translational modification.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/40](#) (for the aspect of post-translational modification).

(35) Antibody wherein the presence, absence or modification by glycosylation, sialylation or fucosylation is an important feature.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/41](#) (glycosylation, sialylation, fucosylation).

(36) Antibody characterised by immunoglobulin fragments. The mere provision of an amino acid or nucleotide sequence is not enough to justify one or more of the following codes:

A group in [C07K 16/00](#) (for the specificity of the antigen binding part), and

Indexing code [C07K 2317/50](#) (fragments in general), and/or

Indexing code [C07K 2317/51](#) (complete heavy chain or Fd fragment), and/or

Indexing code [C07K 2317/515](#) (complete light chain), and/or

Indexing code [C07K 2317/52](#) (Fc or constant region, isotype), and/or

Indexing code [C07K 2317/522](#) (CH1), and/or

Indexing code [C07K 2317/524](#) (CH2), and/or

Indexing code [C07K 2317/526](#) (CH3), and/or

Indexing code [C07K 2317/528](#) (CH4), and/or

DATE: JANUARY 1, 2026

PROJECT RP12806

Indexing code [C07K 2317/53](#) (hinge), and/or

Indexing code [C07K 2317/54](#) (F(ab')₂), and/or

Indexing code [C07K 2317/55](#) (Fab or Fab'), and/or

Indexing code [C07K 2317/56](#) (variable = Fv), and/or

Indexing code [C07K 2317/565](#) (CDR), and/or

Indexing code [C07K 2317/567](#) (framework = FR), and/or

Indexing code [C07K 2317/569](#) (single domain = sdAb or dAb).

Note: The mere provision of an amino acid or nucleotide sequence per se of the above fragment is not enough to justify one or more of the above-mentioned indexing codes, unless said fragment is actually manufactured or modified.

Note: If features of both CDRs (or individual residues therein) and FRs (or individual residues therein) are modified, then both the [C07K 2317/565](#) and [C07K 2317/567](#) codes should be given, and not the general [C07K 2317/56](#) code. The [C07K 2317/56](#) code should be given if the focus is on the intact VH and/or VL domain(s).

Note: Indexing codes in the [C07K 2317/522-C07K 2317/53](#) series should only be given for features, e.g. modifications, concerning these specific domains; otherwise, the [C07K 2317/52](#) code should be given. Said specific domains need not necessarily be in isolated form, but may be in the context of their immunoglobulin molecule or fragments thereof.

(37) Antibody characterised by non-natural combinations of immunoglobulins or fragments. This includes fusion proteins and chemically linked immunoglobulins or their fragments. Excluded are chimeric, humanised or veneered antibodies (see above).

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/60](#) (general aspects), and/or

Indexing code [C07K 2317/622](#) (single chain = scFv), and/or

Indexing code [C07K 2317/624](#) (disulfide stabilised variable = dsFv), and/or

Indexing code [C07K 2317/626](#) (diabody, triabody), and/or

DATE: JANUARY 1, 2026

PROJECT RP12806

Indexing code [C07K 2317/64](#) (comprising a combination of variable region and constant region components), and/or

Indexing code [C07K 2317/66](#) (comprising a swap of domains, e.g. CH3-CH2, VH-CL, VL-CH1).

Optionally, indexing code [C07K 2319/00](#) (if fusion protein).

(38) Antibody characterised by an effect upon binding to a cell or to an antigen.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/71](#) (decreased effector function due to an Fc-modification), and/or

Indexing code [C07K 2317/72](#) (increased effector function due to an Fc-modification), and/or

Indexing code [C07K 2317/73](#) (induction of cell death, e.g. apoptosis, necrosis; inhibition of cell proliferation), and/or

Indexing code [C07K 2317/732](#) (antibody-dependent cellular cytotoxicity (ADCC)), and/or

Indexing code [C07K 2317/734](#) (complement-dependent cytotoxicity (CDC)), and/or

Indexing code [C07K 2317/74](#) (induction of cell proliferation), and/or

Indexing code [C07K 2317/75](#) (agonist effect on antigen), and/or

Indexing code [C07K 2317/76](#) (antagonist effect on antigen, neutralisation, inhibition of binding), and/or

Indexing code [C07K 2317/77](#) (internalisation into the cell).

(39) Antibody characterised by remaining in the (producing) cell, i.e. intracellular antibody = intrabody.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/80](#) (general aspects), and/or

Indexing code [C07K 2317/81](#) (intracellular antibody functional in the ER or Golgi apparatus), and/or

DATE: JANUARY 1, 2026

PROJECT RP12806

Indexing code [C07K 2317/82](#) (intracellular antibody functional in the cytoplasm, the nucleus, the mitochondria, the inner part of the cell membrane).

(40) Antibody characterised by (pharmaco) kinetic aspects or stability of the immunoglobulin.

A group in [C07K 16/00](#) (for the specificity), and

Indexing code [C07K 2317/90](#) (general aspects), or

Indexing code [C07K 2317/92](#) (for affinity (KD), association rate (Ka), dissociation rate (Kd), EC50 value) or

Indexing code [C07K 2317/94](#) (in vivo stability, e.g. half-life, pH-, temperature- or enzyme-resistance; Note: for in vitro/pretreatment storage stability see [A61K 39/39591](#)).

(41) Antibody mimetics and scaffolds.

A group in [C07K 16/00](#) (for the specificity of the inserted antigen binding sequences from antibodies), and

Indexing code [C07K 2318/00](#) (general aspects of antibody mimetics and scaffolds).

(42) Immunoglobulin or domain(s) thereof as scaffolds for inserted non-immunoglobulin peptide sequences, e.g. for vaccination purposes, e.g. synthebody.

A group in [C07K 14/00](#) (for the non-immunoglobulin protein that is inserted), and

A group in [C07K 16/00](#) (for the specificity of the immunoglobulin scaffold), and

Indexing code [C07K 2318/10](#) (to indicate the combination of immunoglobulin scaffold molecules with inserted non-immunoglobulin peptide sequences).

(43) Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics.

A group in [C07K 14/00](#) (for the non-immunoglobulin protein that provides the scaffold).

A group in [C07K 16/00](#) (for the antibody-like specificity of the scaffold molecule).

Indexing code [C07K 2318/20](#) (for scaffold molecules with antigen binding properties).

Guide to the specificity of an antibody for a certain antigen (with synonyms) -
KEYWORD/CLASSIFICATION INDEX (KCI)

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/08](#) - Antigens from viruses
- [C07K 16/081](#) - Antigens from DNA viruses
- [C07K 16/081](#) - Antigens from orthopoxviridae
- [C07K 16/081](#) - Antigens from vaccinia
- [C07K 16/082](#) - Antigens from hepadnaviridae
- [C07K 16/082](#) - Antigens from hepatitis B virus, HBV
- [C07K 16/084](#) - Antigens from papovaviridae
- [C07K 16/084](#) - Antigens from BK virus
- [C07K 16/084](#) - Antigens from JC virus
- [C07K 16/084](#) - Antigens from papillomavirus
- [C07K 16/084](#) - Antigens from polyomavirus
- [C07K 16/084](#) - Antigens from SV40
- [C07K 16/085](#) - Antigens from herpesviridae
- [C07K 16/085](#) - Antigens from pseudorabies virus
- [C07K 16/085](#) - Antigens from EBV, Epstein-Barr virus
- [C07K 16/087](#) - Antigens from HSV, herpes simplex virus
- [C07K 16/088](#) - Antigens from varicella-zoster virus
- [C07K 16/088](#) - Antigens from CMV, cytomegalovirus
- [C07K 16/10](#) - Antigens from RNA viruses
- [C07K 16/10](#) - Antigens from hepatitis E virus, HEV
- [C07K 16/10](#) - Antigens from corona virus
- [C07K 16/10](#) - Antigens from SARS
- [C07K 16/106](#) - Antigens from picornaviridae
- [C07K 16/106](#) - Antigens from hepatitis A virus, HAV
- [C07K 16/108](#) - Antigens from orthomyxoviridae
- [C07K 16/108](#) - Antigens from influenza virus
- [C07K 16/11](#) - Antigens from paramyxoviridae
- [C07K 16/11](#) - Antigens from respiratory syncytial virus, RSV
- [C07K 16/112](#) - Antigens from retroviridae
- [C07K 16/112](#) - Antigens from leukemia viruses
- [C07K 16/114](#) - Antigens from lentiviridae
- [C07K 16/114](#) - Antigens from human immunodeficiency virus, HIV
- [C07K 16/114](#) - Antigens from feline immunodeficiency virus, FIV
- [C07K 16/114](#) - Antigens from simian immunodeficiency virus, SIV
- [C07K 16/1143](#) - Antigens from gag-pol
- [C07K 16/1143](#) - p17
- [C07K 16/1143](#) - p24

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/1145](#) - Antigens from env
- [C07K 16/1145](#) - gp41
- [C07K 16/1145](#) - gp110/120
- [C07K 16/1145](#) - gp160
- [C07K 16/1145](#) - V3
- [C07K 16/1145](#) - PND
- [C07K 16/1145](#) - CD4-binding site
- [C07K 16/1147](#) - Antigens from regulatory proteins
- [C07K 16/1147](#) - tat
- [C07K 16/1147](#) - rev
- [C07K 16/1147](#) - vpt
- [C07K 16/116](#) - Antigens from togaviridae
- [C07K 16/116](#) - Antigens from flavivirus
- [C07K 16/116](#) - Antigens from rubella virus
- [C07K 16/116](#) - Antigens from hog cholera virus
- [C07K 16/118](#) - Antigens from hepatitis C virus, HCV
- [C07K 16/118](#) - Antigens from hepatitis G virus, HGV
- [C07K 16/12](#) - Antigens from bacteria
- [C07K 16/1203](#) - Antigens from Gram-negative bacteria
- [C07K 16/1203](#) - LPS, lipopolysaccharide
- [C07K 16/1207](#) - Antigens from Spirochaetales
- [C07K 16/1207](#) - Antigens from Treponema
- [C07K 16/1207](#) - Antigens from Leptospira
- [C07K 16/121](#) - Antigens from Helicobacter (Campylobacter)
- [C07K 16/1214](#) - Antigens from Pseudomonadaceae
- [C07K 16/1217](#) - Antigens from Neisseriaceae
- [C07K 16/1217](#) - Antigens from Acinetobacter
- [C07K 16/1221](#) - Antigens from Brucella
- [C07K 16/1225](#) - Antigens from Bordetella
- [C07K 16/1228](#) - Antigens from Enterobacteriaceae
- [C07K 16/1228](#) - Antigens from Citrobacter
- [C07K 16/1228](#) - Antigens from Serratia
- [C07K 16/1228](#) - Antigens from Proteus
- [C07K 16/1228](#) - Antigens from Providencia
- [C07K 16/1228](#) - Antigens from Morganella
- [C07K 16/1228](#) - Antigens from Yersinia
- [C07K 16/1232](#) - Antigens from Escherichia

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/1235](#) - Antigens from Salmonella
- [C07K 16/1239](#) - Antigens from Vibrionaceae
- [C07K 16/1242](#) - Antigens from Pasteurellaceae
- [C07K 16/1242](#) - Antigens from Haemophilus influenza
- [C07K 16/1246](#) - Antigens from Rickettsiales
- [C07K 16/125](#) - Antigens from Chlamydiales
- [C07K 16/1253](#) - Antigens from Mycoplasmatales
- [C07K 16/1253](#) - Antigens from Pleuropneumonia-like organisms
- [C07K 16/1257](#) - Antigens from Bacteridaceae
- [C07K 16/126](#) - Antigens from Legionella
- [C07K 16/1264](#) - Antigens from Rhizobiaceae
- [C07K 16/1267](#) - Antigens from Gram-positive bacteria
- [C07K 16/1271](#) - Antigens from Micrococcaceae
- [C07K 16/1271](#) - Antigens from Staphylococcus
- [C07K 16/1271](#) - Antigens from multi-resistant Staphylococcus aureus, MRSA
- [C07K 16/1275](#) - Antigens from Streptococcus
- [C07K 16/1278](#) - Antigens from Bacillus
- [C07K 16/1282](#) - Antigens from Clostridium
- [C07K 16/1282](#) - Botulinum neurotoxin A, BoNT/A
- [C07K 16/1282](#) - Botulinum neurotoxin B, BoNT/B
- [C07K 16/1282](#) - Botulinum neurotoxin C1, BoNT/C1
- [C07K 16/1282](#) - Botulinum neurotoxin D, BoNT/D
- [C07K 16/1282](#) - Botulinum neurotoxin E, BoNT/E
- [C07K 16/1282](#) - Botulinum neurotoxin F, BoNT/F
- [C07K 16/1282](#) - Botulinum neurotoxin G, BoNT/G
- [C07K 16/1282](#) - SNAP-23, synaptosomal-associated protein of 23 kDa
- [C07K 16/1282](#) - SNAP-25, synaptosomal-associated protein of 25 kDa
- [C07K 16/1282](#) - TT, tetanus toxoid
- [C07K 16/1285](#) - from Corynebacterium
- [C07K 16/1285](#) - LLO, listeriolysin
- [C07K 16/1289](#) - Antigens from Mycobacteriaceae
- [C07K 16/1292](#) - Antigens from Actinomyces
- [C07K 16/1292](#) - Antigens from Streptomyces
- [C07K 16/1296](#) - Antigens from Listeria
- [C07K 16/14](#) - Antigens from fungi, alga or lichens
- [C07K 16/14](#) - Streptavidin
- [C07K 16/16](#) - Antigens from plants

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/18](#) - Antigens from animals or humans
- [C07K 16/18](#) - Acetylcholine
- [C07K 16/18](#) - Actin
- [C07K 16/18](#) - ADDL, beta amyloid oligomeric ligand
- [C07K 16/18](#) - Aggrecan
- [C07K 16/18](#) - Annexins
- [C07K 16/18](#) - Apolipoprotein
- [C07K 16/18](#) - Avidin
- [C07K 16/18](#) - Beta amyloid, Abeta, amyloid beta
- [C07K 16/18](#) - CGRP, calcitonin gene-related peptide
- [C07K 16/18](#) - Collagen
- [C07K 16/18](#) - Complement
- [C07K 16/18](#) - (Complement) factor B, fB
- [C07K 16/18](#) - (Complement) factor D, fD
- [C07K 16/18](#) - Cyr61, Cyr-61, cystein-rich protein, GIG-1, IGFBP10, CCN1, insulin growth factor binding protein 10
- [C07K 16/18](#) - Desmin
- [C07K 16/18](#) - DKK-1, DKK1, Dickkopf 1, dickkopf homolog 1
- [C07K 16/18](#) - DKK-2, DKK2, Dickkopf 2, dickkopf homolog 2
- [C07K 16/18](#) - DKK-3, DKK3, Dickkopf 3, dickkopf homolog 3
- [C07K 16/18](#) - DKK-4, DKK4, Dickkopf 4, dickkopf homolog 4
- [C07K 16/18](#) - Dopamine
- [C07K 16/18](#) - Elastin
- [C07K 16/18](#) - Endoplasmic, GRP94, Hsp90B1, ERp99
- [C07K 16/18](#) - Epinephrine, adrenaline (also in [C07K 16/26](#))
- [C07K 16/18](#) - Fatty acid binding protein, FABP
- [C07K 16/18](#) - Fatty acid binding protein 1, FABP 1, FABP1
- [C07K 16/18](#) - Fatty acid binding protein 2, FABP 2, FABP2
- [C07K 16/18](#) - Fatty acid binding protein 3, FABP 3, FABP3
- [C07K 16/18](#) - Fatty acid binding protein 4, FABP 4, FABP4
- [C07K 16/18](#) - Fatty acid binding protein 5, FABP 5, FABP5
- [C07K 16/18](#) - Fatty acid binding protein 6, FABP 6, FABP6
- [C07K 16/18](#) - Fatty acid binding protein 7, FABP 7, FABP7
- [C07K 16/18](#) - Fatty acid binding protein 8, FABP 8, FABP8
- [C07K 16/18](#) - Fatty acid binding protein 9, FABP 9, FABP9
- [C07K 16/18](#) - Fatty acid binding protein 10, FABP 10, FABP10
- [C07K 16/18](#) - Fatty acid binding protein 11, FABP 11, FABP11

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/18](#) - Fatty acid binding protein 12, FABP 12, FABP12
- [C07K 16/18](#) - Fatty acid binding protein 5 like 1
- [C07K 16/18](#) - Fatty acid binding protein 5 like 2
- [C07K 16/18](#) - Fatty acid binding protein 5 like 3
- [C07K 16/18](#) - Fatty acid binding protein 5 like 4
- [C07K 16/18](#) - Fatty acid binding protein 5 like 5
- [C07K 16/18](#) - Fatty acid binding protein 5 like 6
- [C07K 16/18](#) - Fatty acid binding protein 5 like 7
- [C07K 16/18](#) - Ferritin
- [C07K 16/18](#) - Fibrin
- [C07K 16/18](#) - Fibronectin
- [C07K 16/18](#) - Fisp12, fibroblast secreted protein
- [C07K 16/18](#) - Foxp3, SCURFIN
- [C07K 16/18](#) - GAP43, GAP 43, growth associated protein 43, neuromodulin, protein F1, B-50, P57, PP46
- [C07K 16/18](#) - GFAP, glial fibrillary acidic protein
- [C07K 16/18](#) - GRP78, BiP, immunoglobulin binding protein, HSPA5
- [C07K 16/18](#) - Heat shock proteins, HSP
- [C07K 16/18](#) - Heat shock cognate protein 71, HSC71
- [C07K 16/18](#) - Heparin
- [C07K 16/18](#) - HIG-1, hypoxia-induced gene
- [C07K 16/18](#) - Keratin
- [C07K 16/18](#) - Laminin
- [C07K 16/18](#) - Lipocalin, uterocalin, NGAL, LCN2, 24p3
- [C07K 16/18](#) - Lipocortin
- [C07K 16/18](#) - LRG1, leucine rich alpha 2 glycoprotein 1
- [C07K 16/18](#) - LDL, low density lipoprotein
- [C07K 16/18](#) - MCI, multicilin
- [C07K 16/18](#) - MCPH1, microcephalin 1
- [C07K 16/18](#) - MD-2, myeloid differentiation protein 2
- [C07K 16/18](#) - MIG6, MIG-6, RALT, ERRF11, ErbB receptor feedback inhibitor 1
- [C07K 16/18](#) - Myosin
- [C07K 16/18](#) - Nanog
- [C07K 16/18](#) - Neurotensin, NTS (also in [C07K 16/26](#))
- [C07K 16/18](#) - NOD2, CARD-15, IBD1
- [C07K 16/18](#) - Norepinephrine, noradrenaline
- [C07K 16/18](#) - NuIP, Nurr1-interacting protein

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/18](#) - OLFM1, olfactomedin 1
- [C07K 16/18](#) - OLFM2, olfactomedin 2
- [C07K 16/18](#) - OLFM3, olfactomedin 3
- [C07K 16/18](#) - OLFML2b, olfactomedin-like 2b
- [C07K 16/18](#) - OLFML3, olfactomedin-like 3
- [C07K 16/18](#) - Osteocalcin, bone gla protein
- [C07K 16/18](#) - Osteonectin, SPARC, secreted protein acidic and rich in cysteines, BM-40, BM40, basement membrane protein 40
- [C07K 16/18](#) - Ovalbumin
- [C07K 16/18](#) - Ovotransferrin
- [C07K 16/18](#) - OxLDL, oxidised low density lipoprotein, oxidised LDL
- [C07K 16/18](#) - PAMG-1, placental alpha microglobulin 1
- [C07K 16/18](#) - Perforin
- [C07K 16/18](#) - Periostin, POSTN, OSF2, OSF-2, osteoblast-specific factor 2
- [C07K 16/18](#) - Properdin, factor P
- [C07K 16/18](#) - PYY, YY protein
- [C07K 16/18](#) - SAP, SLAM-associated protein, serum amyloid protein
- [C07K 16/18](#) - SATB2, special AT-rich sequence binding protein 2
- [C07K 16/18](#) - SFRP2, secreted frizzled-related protein 2
- [C07K 16/18](#) - SFRP5, secreted frizzled-related protein 5, SARP3
- [C07K 16/18](#) - Shh, sonic hedgehog homolog
- [C07K 16/18](#) - SIP, sphingosine 1 phosphate
- [C07K 16/18](#) - SLIT1
- [C07K 16/18](#) - SLIT2
- [C07K 16/18](#) - Soggy
- [C07K 16/18](#) - Spadin
- [C07K 16/18](#) - SSEA-3, stage-specific embryonic antigen 3
- [C07K 16/18](#) - SSEA-4, stage-specific embryonic antigen 4
- [C07K 16/18](#) - SRF, serum response factor
- [C07K 16/18](#) - SUMO1, SUMO-1, small ubiquitin-like modifier 1
- [C07K 16/18](#) - SUMO2, SUMO-2, small ubiquitin-like modifier 2
- [C07K 16/18](#) - SUMO3, SUMO-3, small ubiquitin-like modifier 3
- [C07K 16/18](#) - SUMO4, SUMO-4, small ubiquitin-like modifier 4
- [C07K 16/18](#) - Synuclein
- [C07K 16/18](#) - Tenascin
- [C07K 16/18](#) - Transferrin
- [C07K 16/18](#) - Troponin

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/18](#) - TTR, transthyretin, CTS, CTS1, PALB, TBPA
- [C07K 16/18](#) - Ubiquitin, APF-1, ATP-dependent proteolysis factor
- [C07K 16/18](#) - Uromodulin, Tamm-Horsfall protein
- [C07K 16/18](#) - Versican, VCAN
- [C07K 16/18](#) - Vimentin
- [C07K 16/18](#) - Vitronectin
- [C07K 16/20](#) - Antigens from protozoa
- [C07K 16/205](#) - Antigens from Plasmodium
- [C07K 16/205](#) - TRAP, thrombospondin-related adhesion molecule
- [C07K 16/22](#) - Growth factors, growth regulators
- [C07K 16/22](#) - Activin
- [C07K 16/22](#) - Activin A
- [C07K 16/22](#) - Activin B
- [C07K 16/22](#) - Activin C
- [C07K 16/22](#) - Activin D
- [C07K 16/22](#) - Activin E
- [C07K 16/22](#) - Adrenomedullin
- [C07K 16/22](#) - Angiogenin
- [C07K 16/22](#) - Angiopoietin
- [C07K 16/22](#) - Angiopoietin 1, Ang-1, Angpt-1, Ang1
- [C07K 16/22](#) - Angiopoietin 2, Ang-2, Angpt-2, Ang2
- [C07K 16/22](#) - Angiopoietin 3, Ang-3, Angpt-3, Ang3
- [C07K 16/22](#) - Angiopoietin 4, Ang-4, Angpt-4, Ang4
- [C07K 16/22](#) - Angiopoietin-like protein 2, Angptl-2, ARP2
- [C07K 16/22](#) - Angiopoietin-like protein 3, Angptl-3, ARP3
- [C07K 16/22](#) - Angiopoietin-like protein 4, Angptl-4, PGAR, BK89, FIAF, fasting-induced adipose factor, HFARP, hepatic fibrinogen/angiopoietin-related protein, FDRG, fibrinogen-domain, TANGO115, PPARgamma, peroxisome proliferator-activated angiopoietin-related gamma
- [C07K 16/22](#) - Angiopoietin-like protein 5, Angptl-5, ARP5
- [C07K 16/22](#) - Angiopoietin-like protein 6, Angptl-6, ARP6
- [C07K 16/22](#) - Angiopoietin-like protein 7, Angptl-7, ARP7
- [C07K 16/22](#) - ARIA
- [C07K 16/22](#) - Artemin, ARTN
- [C07K 16/22](#) - BDNF, brain-derived neurotrophic factor
- [C07K 16/22](#) - bone-inducing factor

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/22](#) - bone morphogenetic factor, bone morphogenetic protein, BMP, morphogen
- [C07K 16/22](#) - ChM-I, ChM-1, chondromodulin 1
- [C07K 16/22](#) - CTGF, connective tissue growth factor
- [C07K 16/22](#) - CTGF-1, connective tissue growth factor 1
- [C07K 16/22](#) - CTGF-2, connective tissue growth factor 2
- [C07K 16/22](#) - Desert hedgehog, Dhh
- [C07K 16/22](#) - EGF, epidermal growth factor, urogastrone
- [C07K 16/22](#) - EGFL7, EGF-like domain multiple 7, EGF like domain 7, Neu1, Zneu1, VE-statin, vascular endothelial statin, RP11-25M1.2, epidermal growth factor like domain 7
- [C07K 16/22](#) - Epiregulin, ER, EREG
- [C07K 16/22](#) - EPO, erythropoietin
- [C07K 16/22](#) - FGF, fibroblast growth factor
- [C07K 16/22](#) - FGF-1, fibroblast growth factor 1, acidic FGF, aFGF, acidic fibroblast growth factor, retinal-derived growth factor, prostatropin, heparin-binding growth factor alpha, HBGF-alpha, eye-derived growth factor 2, ECGF, endothelial cell growth factor, brain-derived growth factor, astroglial growth factor 1, delta-15 beta endothelial growth factor, HBGF-1, heparin-binding growth factor 1
- [C07K 16/22](#) - FGF-2, fibroblast growth factor 2, basic FGF, bFGF, basic fibroblast growth factor, macrophage growth factor, hepatoma-derived growth factor, heparin-binding growth factor beta, eye-derived growth factor 1, chondrosarcoma-derived growth factor, cartilage-derived growth factor, astroglial growth factor 2
- [C07K 16/22](#) - FGF-3, fibroblast growth factor 3, INT-2 oncogene
- [C07K 16/22](#) - FGF-4, fibroblast growth factor 4, heparin-binding secretory transforming factor, HST-1, human transforming protein, HST, human Kaposi sarcoma oncogene
- [C07K 16/22](#) - FGF-5, fibroblast growth factor 5
- [C07K 16/22](#) - FGF-6, fibroblast growth factor 6, HST-2
- [C07K 16/22](#) - FGF-7, fibroblast growth factor 7, SDGF-3, spleen-derived growth factor 3, HBGF-7, heparin-binding growth factor 7
- [C07K 16/22](#) - FGF-8, fibroblast growth factor 8, AIGF, androgen-induced growth factor
- [C07K 16/22](#) - FGF-9, fibroblast growth factor 9, GAF, glia activating factor
- [C07K 16/22](#) - FGF-10, fibroblast growth factor 10

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/22](#) - FGF-11, fibroblast growth factor 11, FHF-1, FGF homologous factor 1, fibroblast growth factor homologous factor 1
- [C07K 16/22](#) - FGF-12, fibroblast growth factor 12, FHF-2, FGF homologous factor 2, fibroblast growth factor homologous factor 2, KGF-2, keratinocyte growth factor 2
- [C07K 16/22](#) - FGF-13, fibroblast growth factor 13, FHF-3, FGF homologous factor 3, fibroblast growth factor homologous factor 3
- [C07K 16/22](#) - FGF-14, fibroblast growth factor 14, FHF-4, FGF homologous factor 4, fibroblast growth factor homologous factor 4
- [C07K 16/22](#) - FGF-15, fibroblast growth factor 15
- [C07K 16/22](#) - FGF-CX, fibroblast growth factor CX
- [C07K 16/22](#) - Fibulin 5, FBLN-5, DANCE, EVEC
- [C07K 16/22](#) - GDF-8, growth and differentiation factor 8, myostatin, mstn
- [C07K 16/22](#) - GDF-15, growth and differentiation factor 15, MIC-1, macrophage inhibitory cytokine 1, PDF, prostate-derived factor, PLAB, placental bone morphogenetic protein
- [C07K 16/22](#) - GDNF, glial-derived neurotrophic factor, glial cell-derived neurotrophic factor
- [C07K 16/22](#) - Glial growth factor
- [C07K 16/22](#) - HB-EGF, heparin-binding EGF-like growth factor
- [C07K 16/22](#) - HBGF-2, heparin-binding growth factor 2
- [C07K 16/22](#) - Hedgehog, Hh
- [C07K 16/22](#) - Heregulin, HRG, Neu differentiation factor, NDF
- [C07K 16/22](#) - Heregulin alpha, HRG-alpha,
- [C07K 16/22](#) - Heregulin beta1, HRG-beta1
- [C07K 16/22](#) - Heregulin beta2, HRG-beta2
- [C07K 16/22](#) - Heregulin beta2-like, HRG-beta2-like
- [C07K 16/22](#) - Heregulin gamma, HRG-gamma
- [C07K 16/22](#) - Indian hedgehog, Ihh
- [C07K 16/22](#) - Insulin-like growth factors, IGF, somatomedins
- [C07K 16/22](#) - Insulin-like growth factor 1, IGF-1
- [C07K 16/22](#) - Insulin-like growth factor 2, IGF-2
- [C07K 16/22](#) - HGF, hepatocyte growth factor
- [C07K 16/22](#) - MK, midkine, amphiregulin associated protein, ARAP, NEGF2, neurite growth promoting factor 2, neurite outgrowth promoting factor 2, neurite outgrowth promoting protein

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/22](#) - MSP, macrophage stimulating protein, HGFL, hepatocyte growth factor- like, MST-1
- [C07K 16/22](#) - Netrin 1
- [C07K 16/22](#) - Netrin 2
- [C07K 16/22](#) - Netrin 3
- [C07K 16/22](#) - Netrin 4
- [C07K 16/22](#) - neuregulin
- [C07K 16/22](#) - NGF, nerve growth factor
- [C07K 16/22](#) - NOGO
- [C07K 16/22](#) - NT-3, neurotrophin 3
- [C07K 16/22](#) - NT-4/5, neurotrophin 4/5
- [C07K 16/22](#) - neurturin, NTN, NRTN
- [C07K 16/22](#) - osteogenin
- [C07K 16/22](#) - PCDGF, PC cell derived growth factor, epithelin/granulin precursor, gp88
- [C07K 16/22](#) - Persephin, PSN, PSPN
- [C07K 16/22](#) - PDGF, platelet derived growth factor
- [C07K 16/22](#) - PDGF-A, platelet derived growth factor A
- [C07K 16/22](#) - PDGF-B, platelet derived growth factor B
- [C07K 16/22](#) - PDGF-C, platelet derived growth factor C, VEGF-R, zVEGF3
- [C07K 16/22](#) - PDGF-D, platelet derived growth factor D
- [C07K 16/22](#) - PIGF, placental growth factor
- [C07K 16/22](#) - Prokineticin 1, pk1, prok1, EG-VEGF, endocrinal gland-derived vascular endothelial growth factor
- [C07K 16/22](#) - Prokineticin 2, pk2, prok2, bv8
- [C07K 16/22](#) - RGM, repulsive guidance molecule
- [C07K 16/22](#) - RGM-A, repulsive guidance molecule A
- [C07K 16/22](#) - RGM-B, repulsive guidance molecule B
- [C07K 16/22](#) - RGM-C, repulsive guidance molecule C
- [C07K 16/22](#) - Sclerostin
- [C07K 16/22](#) - SKCG-1, SKCG1
- [C07K 16/22](#) - Sonic hedgehog, Shh
- [C07K 16/22](#) - TGF, transforming growth factor
- [C07K 16/22](#) - TGFalpha, TGF alpha, transforming growth factor alpha, TGFa
- [C07K 16/22](#) - TGFbeta, TGF beta, transforming growth factor beta, TGFb
- [C07K 16/22](#) - VEGF, vascular endothelial growth factor
- [C07K 16/22](#) - VEGF-C, vascular endothelial growth factor C, Flt4 ligand, Flt4-L

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/22](#) - VRP, VEGF-related protein
- [C07K 16/22](#) - WISP-1
- [C07K 16/22](#) - WISP-2
- [C07K 16/22](#) - WISP-3
- [C07K 16/22](#) - Wnt1, wnt-1
- [C07K 16/22](#) - Wnt2, wnt-2
- [C07K 16/22](#) - Wnt3, wnt-3
- [C07K 16/22](#) - Wnt5A, wnt-5A
- [C07K 16/22](#) - Wnt7A, wnt-7A
- [C07K 16/22](#) - Wnt7B, wnt-7B
- [C07K 16/22](#) - Wnt8B, wnt-8B
- [C07K 16/22](#) - Wnt10B, wnt-10B
- [C07K 16/22](#) - Wnt11, wnt-11
- [C07K 16/22](#) - Wntx, wnt-x
- [C07K 16/24](#) - Cytokines, lymphokines, chemokines, interferons
- [C07K 16/24](#) - Calgranulin A, MRP8, S100A8, calcium binding protein A8, CABP-P8, 60B8-B, cystic fibrosis antigen
- [C07K 16/24](#) - Calgranulin B, MRP14, S100A9, calcium binding protein A9
- [C07K 16/24](#) - CXCL1, GROalpha, GRO-alpha, growth-related oncogene alpha, MGSAalpha, MGSA-alpha, melanoma growth stimulatory activity alpha, NAP-3, neutrophil-activating peptide 3, Gro-1 alpha
- [C07K 16/24](#) - CXCL2, GRObeta, GRO-beta, growth-related oncogene beta, MGSAbeta, MGSA-beta, melanoma growth stimulatory activity beta, MIP-2 alpha, macrophage inflammatory protein 2 alpha, Gro-1 beta
- [C07K 16/24](#) - CXCL3, GROgamma, GRO-gamma, growth-related oncogene gamma, MGSAgamma, MGSA-gamma, melanoma growth stimulatory activity gamma, MIP-2 beta, macrophage inhibitory protein 2 beta, Gro-1 gamma
- [C07K 16/24](#) - CXCL4, PF4, plasma factor 4, oncostatin A
- [C07K 16/24](#) - CXCL5, ENA-78, epithelial cell-derived neutrophil attractant 78
- [C07K 16/24](#) - CXCL6, GCP-2, granulocyte chemotactic peptide 2, LPS-induced CXC, LIX
- [C07K 16/24](#) - CXCL7, NAP-2, neutrophil-activating protein 2, CTAP-3, connective tissue activating protein 3, LA-PF4, low affinity platelet factor 4, PBP, platelet basic protein, beta thromboglobulin
- [C07K 16/24](#) - CXCL9, Mig, monokine induced by IFN-gamma, CRG-10, cytokine responsive gene 10

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/24](#) - CXCL10, IP-10, interferon-inducible protein 10, immune protein 10, CRG-2, cytokine responsive gene 2
- [C07K 16/24](#) - CXCL11, I-TAC, interferon-inducible T cell alpha chemoattractant, IP-9, interferon-gamma inducible protein 9
- [C07K 16/24](#) - CXCL12, SDF-1, stromal cell-derived factor 1, PBSF, pre-B cell growth stimulating factor
- [C07K 16/24](#) - CXCL13, BLC, B lymphocyte chemoattractant, BCA-1, B cell attracting chemokine 1
- [C07K 16/24](#) - CXCL14, BRAK, CXC chemokine in breast and kidney, BMAC, B cell and monocyte activating chemokine, bolekin
- [C07K 16/24](#) - CXCL15, WECH, weird chemokine
- [C07K 16/24](#) - CCL1, I-309, TCA-3, p500
- [C07K 16/24](#) - CCL2, MCP-1, monocyte chemoattractant protein 1, MCAF, monocyte chemoattractant and activating factor, GDCF, glioma cell-derived chemotactic factor, tumor necrosis factor-stimulated gene sequence 8, monocyte chemotactic protein 1
- [C07K 16/24](#) - CCL3, MIP-1alpha, MIP-1 alpha, macrophage inflammatory protein 1alpha, macrophage inflammatory protein 1 alpha, GOS-19, G0/G1 switch gene
- [C07K 16/24](#) - CCL4, MIP-1beta, MIP-1 beta, macrophage inflammatory protein 1beta, macrophage inflammatory protein 1 beta, ACT-2, immune activation gene 2
- [C07K 16/24](#) - CCL5, RANTES, regulated upon activation normal T cell expressed and secreted, EoCP-1, eosinophil chemotactic polipeptide 1, SIS-delta, small inducible secreted chemokine delta
- [C07K 16/24](#) - CCL6, C10, MRP-1, macrophage inflammatory protein-related protein 1
- [C07K 16/24](#) - CCL7, MCP-3, monocyte chemoattractant protein 3, MARC, mast cell activation-related chemokine, NC28
- [C07K 16/24](#) - CCL8, MCP-2, monocyte chemoattractant protein 2
- [C07K 16/24](#) - CCL9, MIP-1gamma, MIP-1 gamma, macrophage inflammatory protein 1gamma, macrophage inflammatory protein 1 gamma, CCF18
- [C07K 16/24](#) - CCL10
- [C07K 16/24](#) - CCL11, eotaxin
- [C07K 16/24](#) - CCL12, MCP-5, monocyte chemotactic protein 5
- [C07K 16/24](#) - CCL13, MCP-4, monocyte chemotactic protein 4

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/24](#) - CCL14, HCC-1, hemofiltrate CC chemokine 1, M-CIF, macrophage colony inhibitory factor
- [C07K 16/24](#) - CCL15, MIP-5, macrophage inflammatory protein 5, HCC-2, hemofiltrate CC chemokine 2, NCC-3, leukotactin 1
- [C07K 16/24](#) - CCL16, LEC, NCC-4, HCC-4, hemofiltrate CC chemokine 4, new CC chemokine 4, liver-expressed chemokine, monotactin 1
- [C07K 16/24](#) - CCL17, TARC, ABCD-2, thymus and activation-regulated cytokine
- [C07K 16/24](#) - CCL18, DC-CK1, PARC, AMAC-1, dendritic cell-derived chemokine 1, pulmonary and activation-regulated chemokine, alternative activated macrophage-associated CC chemokine
- [C07K 16/24](#) - CCL19, ELC, exodus-3, EBI-1 ligand chemokine
- [C07K 16/24](#) - CCL20, LARC, exodus-1, liver and activation-regulated chemokine
- [C07K 16/24](#) - CCL21, SLC, exodus-2, 6Ckine, secondary lymphoid tissue chemokine
- [C07K 16/24](#) - CCL22, MDC, STCP-1, DC/B-CK, macrophage-derived chemokine, stimulated T cell chemoattractant protein 1
- [C07K 16/24](#) - CCL23, MPIF-1, myeloid progenitor inhibitory factor 1, chemokine beta8, chemokine beta 8
- [C07K 16/24](#) - CCL24, MPIF-2, eotaxin-2, myeloid progenitor inhibitory factor 2, chemokine beta6, chemokine beta 6
- [C07K 16/24](#) - CCL25, TECK, thymus-expressed chemokine
- [C07K 16/24](#) - CCL26, MIP-4alpha, MIP-4 alpha, TSC-1, eotaxin-3, macrophage inflammatory protein 4alpha, macrophage inflammatory protein 4 alpha, thymic stroma chemokine 1
- [C07K 16/24](#) - CCL27, CTACK, MILC, ILC, cutaneous T cell attracting chemokine, ALP, skinkine, eskine
- [C07K 16/24](#) - CCL28, MEC, mucosa-associated epithelial chemokine
- [C07K 16/24](#) - CCL3-L1, MIP-1alphaP, MIP1AP, LD78beta
- [C07K 16/24](#) - Chemerin, RARRES2, RARRES-2, retinoic acid receptor responder 2, TIG2, TIG-2, tazarotene induced gene 2 product
- [C07K 16/24](#) - CK alpha 5, CKalpha-5, chemokine alpha 5
- [C07K 16/24](#) - CK alpha 6, CKalpha-6, chemokine alpha 6
- [C07K 16/24](#) - endokine alpha
- [C07K 16/24](#) - HMGB1, high mobility group box protein 1, HMG-1, high mobility group protein 1

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/24](#) - HMGB2, high mobility group box protein 2, HMG-2, high mobility group protein 2
- [C07K 16/24](#) - HMGB3, high mobility group box protein 3
- [C07K 16/24](#) - HMGB8, high mobility group box protein 8
- [C07K 16/24](#) - HMGB17, high mobility group box protein 17
- [C07K 16/24](#) - HMGBI, high mobility group box protein I
- [C07K 16/24](#) - HMGBY, high mobility group box protein Y
- [C07K 16/24](#) - HMGBI(Y), high mobility group box protein I(Y)
- [C07K 16/24](#) - HMGBI-C, high mobility group box protein I-C
- [C07K 16/24](#) - IRAP, interleukin receptor antagonist protein
- [C07K 16/24](#) - Limitin
- [C07K 16/24](#) - MIF, MMIF, macrophage migration inhibitory factor
- [C07K 16/24](#) - OPN, osteopontin
- [C07K 16/24](#) - SCF, stem cell factor, c-kit ligand
- [C07K 16/24](#) - SMAF1, SMAF-1, suppressive macrophage activation factor 1
- [C07K 16/24](#) - SMAF2, SMAF-2, suppressive macrophage activation factor 2
- [C07K 16/24](#) - thrombopoietin, TPO, MPL ligand
- [C07K 16/24](#) - WSX
- [C07K 16/24](#) - XCL1, lymphotactin, Ltn, Lptn, SCM-1alpha, SCM-1 alpha, single C motif 1alpha, ATAC, activation-induced T cell-derived and chemokine related
- [C07K 16/24](#) - XCL2, SCM-1beta, SCM-1 beta, single C motif 1beta
- [C07K 16/24](#) - zalpha11 ligand
- [C07K 16/24](#) - Zcyto10
- [C07K 16/241](#) - TNF, tumor necrosis factor, tumour necrosis factor
- [C07K 16/241](#) - CD250, TNFalpha, TNF alpha, tumor necrosis factor alpha, tumour necrosis factor alpha, cachectin, TNFSF2, tumor necrosis factor (ligand) superfamily member 2
- [C07K 16/242](#) - TNFbeta, TNF beta, tumor necrosis factor beta, tumour necrosis factor beta, LTalpha, LT alpha, lymphotoxin alpha, TNFSF1, tumor necrosis factor (ligand) superfamily member 1
- [C07K 16/242](#) - LTbeta, LT beta, lymphotoxin beta, p33, TNFC, TNFSF3, tumor necrosis factor (ligand) superfamily member 3
- [C07K 16/243](#) - CSF, colony stimulating factors
- [C07K 16/243](#) - G-CSF, granulocyte colony stimulating factor, granulocyte CSF, CSF3, CSF-3

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/243](#) - GM-CSF, granulocyte-macrophage colony stimulating factor, granulocyte-macrophage CSF
- [C07K 16/243](#) - M-CSF, macrophage colony stimulating factor, macrophage CSF, CSF1, CSF-1
- [C07K 16/244](#) - IL, interleukin
- [C07K 16/244](#) - IL-3, interleukin-3, HCGF, MCGF, multi-SCF
- [C07K 16/244](#) - IL-5, interleukin-5, BCGF-2, BCDF, Eo-CSF
- [C07K 16/244](#) - IL-7, interleukin-7, PBGF, LP-1
- [C07K 16/244](#) - IL-8, interleukin-8, CXCL8, NAP-1, neutrophil activating protein 1, NAF, neutrophil-activating factor, LAI, leukocyte adhesion inhibitor, GCP, granulocyte chemotactic protein, ENAP-beta, endothelial cell neutrophil-activating peptide
- [C07K 16/244](#) - IL-9, interleukin-9, MCGF
- [C07K 16/244](#) - IL-10, interleukin-10, CSIF, TGIF
- [C07K 16/244](#) - IL-11, interleukin-11, megakaryocyte CSF
- [C07K 16/244](#) - IL-12, interleukin-12, p40p35
- [C07K 16/244](#) - IL-12A, interleukin-12A
- [C07K 16/244](#) - IL-12B, interleukin-12B
- [C07K 16/244](#) - IL-13, interleukin-13, NC30, p600
- [C07K 16/244](#) - IL-14, interleukin-14, HMW-BCGF, high-molecular weight B cell growth factor, 60K-BCGF, Namalwa BCGF
- [C07K 16/244](#) - IL-15, interleukin-15, IL-T
- [C07K 16/244](#) - IL-16, interleukin-16, LCF, lymphocyte chemoattractant factor
- [C07K 16/244](#) - IL-17, interleukin-17, CTLA-8
- [C07K 16/244](#) - IL-17B, interleukin-17B
- [C07K 16/244](#) - IL-17C, interleukin-17C
- [C07K 16/244](#) - IL-17D, interleukin-17D
- [C07K 16/244](#) - IL-17E, interleukin-17E
- [C07K 16/244](#) - IL-17F, interleukin-17F
- [C07K 16/244](#) - IL-18, interleukin-18, IGIF, IFN-gamma inducing factor
- [C07K 16/244](#) - IL-19, interleukin-19
- [C07K 16/244](#) - IL-20, interleukin-20, zcyto10
- [C07K 16/244](#) - IL-21, interleukin-21
- [C07K 16/244](#) - IL-22, interleukin-22, IL-TIF, IL-10 related T cell derived inducible factor
- [C07K 16/244](#) - IL-23, interleukin-23, p19p40
- [C07K 16/244](#) - IL-23 p19 subunit, IL-B30

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/244](#) IL-24, interleukin-24, ST16, suppression of tumorigenicity 16, MDA-7, melanoma differentiation associated gene 7, mob-5 (rat), c49a (rat), FISP (mouse)
- [C07K 16/244](#) - IL-25, interleukin-25, SF20
- [C07K 16/244](#) - IL-26, interleukin-26, AK155, ML-1 (?)
- [C07K 16/244](#) - IL-27, interleukin-27, EB13, Epstein-Barr virus-induced gene 3
- [C07K 16/244](#) - IL-28A, interleukin-28A, IFN lambda 1
- [C07K 16/244](#) - IL-28B, interleukin 28B, IFN lambda 2
- [C07K 16/244](#) - IL-29, interleukin-29, IFN lambda 3
- [C07K 16/244](#) - IL-30, interleukin-30, p28
- [C07K 16/244](#) - IL-31, interleukin-31
- [C07K 16/244](#) - IL-32, interleukin-32, NK4, TAIF
- [C07K 16/244](#) - IL-33, interleukin-33, IL-100, interleukin-100
- [C07K 16/244](#) - IL-50, interleukin-50, TSLP, thymic stromal lymphopoietin
- [C07K 16/244](#) - LIF, leukemia inhibitory factor, myeloid differentiation stimulating factor, MDSF, cholinergic differentiation factor, D factor, emfilermin, AM424, AMRAD
- [C07K 16/245](#) - IL-1, interleukin-1, APPIF, adherence-promoting factor, acute phase protein inducing factor, BCDF, B cell differentiation factor
- [C07K 16/245](#) - IL-1alpha, LAF, MCF, IL-1a
- [C07K 16/245](#) - IL-1beta, IFN-beta-inducing factor, OAF, catabolin, IL-1b
- [C07K 16/246](#) - IL-2, interleukin-2, T cell growth factor, blastogenic factor, LMF, lymphocyte mitogenic factor, LPF, lymphocyte proliferation factor, SCIF, secondary cytotoxic T cell inducing factor, TDF, thymocyte differentiation factor, TMF, thymocyte mitogenic factor, T cell maturation factor, T cell mitogenic factor, TSF, thymocyte stimulation factor
- [C07K 16/247](#) - IL-4, interleukin-4, IaIF, (MHC class II) Ia inducing factor, BCDF epsilon, BCDF gamma, B cell differentiation factor epsilon, B cell differentiation factor gamma, BCGF gamma, B cell growth factor gamma, BCGF-1, B cell growth factor 1, BSF-1, B cell stimulating factor 1, HCGF, Hodgkin's cell growth factor, IgE-EF, IgE enhancing factor, IgG1 enhancing factor, LMW-BCGF, low molecular weight B cell growth factor, MCGF-2, mast cell growth factor 2, MFF, macrophage fusion factor, TCGF-1, T cell growth factor 2
- [C07K 16/248](#) - IL-6, interleukin-6, 26 kD protein, BCDF, B cell differentiation factor, BCSF, B cell stimulating factor, BSF-2, B cell stimulating factor 2, CDF, cytotoxic T cell differentiation factor, CPA, CSF-309, DIF, FDGI, FSF, fibronectin stimulating factor, HGF, hybridoma growth factor, HGI, HPGF, HSF, hepatocyte stimulating factor, IFNbeta2, IFN beta 2, interferon beta 2, ILHP1,

DATE: JANUARY 1, 2026

PROJECT RP12806

L-HGF, MGI-2A, MGF, myeloma growth factor, NKAf, natural killer cell activating factor, PCTGF, plasmacytoma growth factor, TAF, T cell activating factor, thymocyte growth factor, TSF, thymocyte stimulating factor

- [C07K 16/248](#) - OSM, oncostatin
- [C07K 16/249](#) - IFN, interferons
- [C07K 16/249](#) - IFNalpha, IFN-alpha, interferon alpha, alpha interferon, IFNa
- [C07K 16/249](#) - IFNbeta, IFN-beta, interferon beta, beta interferon, IFNb
- [C07K 16/249](#) - IFNgamma, IFN-gamma, interferon gamma, gamma interferon, IFNg
- [C07K 16/26](#) - Hormones, neuropeptides
- [C07K 16/26](#) - Adiponectin
- [C07K 16/26](#) - Alarin
- [C07K 16/26](#) - Angiotensin
- [C07K 16/26](#) - Anti-Müllerian hormone, AMH, Müllerian inhibiting factor, MIF, Müllerian inhibiting hormone, MIH, Müllerian inhibiting substance, MIS
- [C07K 16/26](#) - Apelin
- [C07K 16/26](#) - Atrial natriuretic factor complex
- [C07K 16/26](#) - Atriopeptin
- [C07K 16/26](#) - Atrial natriuretic peptide, ANP, natriuretic peptide type A
- [C07K 16/26](#) - Brain natriuretic peptide, BNP, natriuretic peptide type B
- [C07K 16/26](#) - Bombesin
- [C07K 16/26](#) - Calcitonins
- [C07K 16/26](#) - Calcitonin gene-related peptide
- [C07K 16/26](#) - Cardionatrin
- [C07K 16/26](#) - Cardiodilatin
- [C07K 16/26](#) - Cholecystokinins, CCK
- [C07K 16/26](#) - Chorionic gonadotropins, HCG
- [C07K 16/26](#) - Chorionic somatomammotropin
- [C07K 16/26](#) - Corticotropin
- [C07K 16/26](#) - Corticotropin releasing factor, CRF, urotensin
- [C07K 16/26](#) - C-type natriuretic peptide, CNP, natriuretic peptide type C
- [C07K 16/26](#) - Endorphins
- [C07K 16/26](#) - Endothelin
- [C07K 16/26](#) - Enkephalins
- [C07K 16/26](#) - Epinephrine, adrenaline (also in [C07K 16/18](#))
- [C07K 16/26](#) - Follicle-stimulating hormone, FSH
- [C07K 16/26](#) - Galanin, GAL

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/26](#) - Galanin-like peptide, GALP
- [C07K 16/26](#) - Gastrins
- [C07K 16/26](#) - Gastrin releasing peptide
- [C07K 16/26](#) - Ghrelin
- [C07K 16/26](#) - GIP, gastric inhibitory polypeptide, glucose-dependent insulinotropic polypeptide
- [C07K 16/26](#) - Glucagon
- [C07K 16/26](#) - GLP-1, glucagon-like peptide 1
- [C07K 16/26](#) - GLP-2, glucagon-like peptide 2
- [C07K 16/26](#) - Growth hormones, GH, somatotropin
- [C07K 16/26](#) - Growth hormone releasing factors, GHRF
- [C07K 16/26](#) - Hepcidin
- [C07K 16/26](#) - Insulins
- [C07K 16/26](#) - Leptin
- [C07K 16/26](#) - Lipotropins
- [C07K 16/26](#) - Luteinising hormone, LH
- [C07K 16/26](#) - Melanocyte stimulating hormone, MSH
- [C07K 16/26](#) - Melanotropin
- [C07K 16/26](#) - Motilins
- [C07K 16/26](#) - Neurotensin, NTS (also in [C07K 16/18](#))
- [C07K 16/26](#) - Orphan glycoprotein hormone, OGH
- [C07K 16/26](#) - Parathyroid hormone, parathormone
- [C07K 16/26](#) - Parathyroid hormone related peptides
- [C07K 16/26](#) - Prolactin
- [C07K 16/26](#) - Prostaglandins
- [C07K 16/26](#) - Prostaglandin E2, PGE2
- [C07K 16/26](#) - Relaxins
- [C07K 16/26](#) - Salusin alpha
- [C07K 16/26](#) - Salusin beta
- [C07K 16/26](#) - Secretins
- [C07K 16/26](#) - Serotonin
- [C07K 16/26](#) - Somatostatins
- [C07K 16/26](#) - Substance P
- [C07K 16/26](#) - TFF1, TFF-1, trefoil factor 1, trefoil factor family 1, BCEI, PS2, D21S21, HP1-A, PNR2, breast cancer estrogen-inducible protein, breast cancer estrogen-inducible sequence

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/26](#) - TFF2, TFF-2, trefoil factor 2, trefoil factor family 2, AML1, spasmodic, spasmodic polypeptide, human spasmodic polypeptide
- [C07K 16/26](#) - TFF3, TFF-3, trefoil factor 3, ITF, intestinal trefoil factor, HITF, human intestinal trefoil factor, trefoil factor family 3
- [C07K 16/26](#) - Thymopoietins
- [C07K 16/26](#) - Thymosin
- [C07K 16/26](#) - Thyroid stimulating hormone, TSH
- [C07K 16/26](#) - Vasoactive intestinal contractor, VIC
- [C07K 16/26](#) - Vasoactive intestinal peptide, VIP
- [C07K 16/26](#) - Vasopressin
- [C07K 16/26](#) - zalpha48
- [C07K 16/26](#) - zsig57
- [C07K 16/28](#) - cell surface receptors/determinants/molecules
- [C07K 16/28](#) - ARMP, Alzheimer-related membrane protein
- [C07K 16/28](#) - Beclin-1, BECN1, BECN-1, protein GT197, ATG6, ATG-6, coiled-coil myosin-like BCL2-interacting protein, autophagy related gene 6
- [C07K 16/28](#) - CAP1, CAP-1, adenylyl cyclase-associated protein 1
- [C07K 16/28](#) - CAP2, CAP-2, adenylyl cyclase-associated protein 2
- [C07K 16/28](#) - Caprin-1, caprin1, M11S1, RNF105, p137GPI, GPIAP1, GPIp137
- [C07K 16/28](#) - Caveolin
- [C07K 16/28](#) - Cav1, cav-1, caveolin 1
- [C07K 16/28](#) - Cav2, cav 2, caveolin 2
- [C07K 16/28](#) - Cav3, cav 3, caveolin 3
- [C07K 16/28](#) - CLASP-1, cadherin-like asymmetry protein 1
- [C07K 16/28](#) - CLASP-2, cadherin-like asymmetry protein 2
- [C07K 16/28](#) - CLASP-3, cadherin-like asymmetry protein 3
- [C07K 16/28](#) - CLASP-4, cadherin-like asymmetry protein 4
- [C07K 16/28](#) - CLASP-5, cadherin-like asymmetry protein 5
- [C07K 16/28](#) - CLASP-6, cadherin-like asymmetry protein 6
- [C07K 16/28](#) - CLDN1, claudin-1
- [C07K 16/28](#) - CLDN2, claudin-2
- [C07K 16/28](#) - CLDN3, claudin-3, RVP1, RVP-1
- [C07K 16/28](#) - CLDN4, claudin-4, Clostridium perfringens enterotoxin receptor
- [C07K 16/28](#) - CLDN5, claudin-5, TMVCF
- [C07K 16/28](#) - CLDN6, claudin-6
- [C07K 16/28](#) - CLDN7, claudin-7

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/28](#) - CLDN8, claudin-8
- [C07K 16/28](#) - CRACM1, Orai1, calcium release activated Ca²⁺ channel modulator 1
- [C07K 16/28](#) - CRACM2, calcium release activated Ca²⁺ channel modulator 2
- [C07K 16/28](#) - CRACM3, calcium release activated Ca²⁺ channel modulator 3
- [C07K 16/28](#) - DCAL-2
- [C07K 16/28](#) - Delta
- [C07K 16/28](#) - Delta-like 1, Dlk-1, DLK1
- [C07K 16/28](#) - Desmoglein
- [C07K 16/28](#) - EMP2, EMP-2, epithelial membrane protein 2
- [C07K 16/28](#) - Ephrin A1, EFNA1
- [C07K 16/28](#) - Ephrin A2, EFNA2
- [C07K 16/28](#) - Ephrin A3, EFNA3
- [C07K 16/28](#) - Ephrin A4, EFNA4
- [C07K 16/28](#) - Ephrin A5, EFNA5
- [C07K 16/28](#) - Ephrin B1, EFNB1
- [C07K 16/28](#) - Ephrin B2, EFNB2
- [C07K 16/28](#) - Ephrin B3, EFNB3
- [C07K 16/28](#) - ESDN, endothelial and smooth muscle cell-derived neuropilin-like molecule
- [C07K 16/28](#) - FXYD5, dysadherin
- [C07K 16/28](#) - Ferroportin, IREG-1, MTP-1, SLC40A1, iron regulated transported protein 1
- [C07K 16/28](#) - FOLR1, FOLR-1, folate receptor 1
- [C07K 16/28](#) - FOLR2, FOLR-2, folate receptor 2
- [C07K 16/28](#) - FOLR3, FOLR-3, folate receptor 3
- [C07K 16/28](#) - gpr34
- [C07K 16/28](#) - gpr87, FKSG78, GPR95, G-protein-coupled receptor 95, G-protein-coupled receptor 87, KPG002, MGC131898
- [C07K 16/28](#) - GCTM-5
- [C07K 16/28](#) - HEA, human epithelial antigen
- [C07K 16/28](#) - HICSP, heat-inducible cell surface protein
- [C07K 16/28](#) - HJV, hemojuvelin, HFE2, RGMc
- [C07K 16/28](#) - Jagged 2, HJ2
- [C07K 16/28](#) - LRP-1, LRP1, LDL receptor-related protein 1
- [C07K 16/28](#) - LRP-1b, LRP1b, LDL receptor-related protein 1b
- [C07K 16/28](#) - LRP-2, LRP2, LDL receptor-related protein 2

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/28](#) - LRP-4, LRP4, LDL receptor-related protein 4
- [C07K 16/28](#) - LRP-4, LRP4, LDL receptor-related protein 4
- [C07K 16/28](#) - LRP-5, LRP5, LDL receptor-related protein 5
- [C07K 16/28](#) - LRP-6, LRP6, LDL receptor-related protein 6
- [C07K 16/28](#) - LRP-8, LRP8, LDL receptor-related protein 8
- [C07K 16/28](#) - LOX-1
- [C07K 16/28](#) - Ly6D, E48
- [C07K 16/28](#) - MARCO, macrophage receptor with collagenous structure
- [C07K 16/28](#) - MCEMP, mast cell-expressed membrane protein
- [C07K 16/28](#) - MFAP4, microfibrillar-associated protein 4
- [C07K 16/28](#) - Notch, Lin-12, Tan 1
- [C07K 16/28](#) - Occludin, OCLN
- [C07K 16/28](#) - OPRM1, OPRM-1, MOR-1, mu (type) opioid receptor
- [C07K 16/28](#) - PAR1, PAR-1, protease-activated receptor 1, protease/proteinase-activated receptor 1
- [C07K 16/28](#) - PAR2, PAR-2, protease-activated receptor 2, C140, protease/proteinase-activated receptor 2
- [C07K 16/28](#) - P-cadherin, CDH3
- [C07K 16/28](#) - Piezo1, piezo-1, FAM38A, KIAA0233
- [C07K 16/28](#) - Piezo2, piezo-2
- [C07K 16/28](#) - RE2-L, RE2-like, GPR101
- [C07K 16/28](#) - SAS1R, sperm acrosomal SLLP1 receptor
- [C07K 16/28](#) - scavenger receptor B1, SC-BI, SC-B1, CLA-1, SR-B1
- [C07K 16/28](#) - SEL-OB, SVEP1
- [C07K 16/28](#) - Serrate
- [C07K 16/28](#) - SLITRK1, SLIT and NTRK-like protein 1
- [C07K 16/28](#) - SLITRK2, SLIT and NTRK-like protein 2
- [C07K 16/28](#) - SLITRK3, SLIT and NTRK-like protein 3
- [C07K 16/28](#) - SLITRK4, SLIT and NTRK-like protein 4
- [C07K 16/28](#) - SLITRK5, SLIT and NTRK-like protein 5
- [C07K 16/28](#) - SLITRK6, SLIT and NTRK-like protein 6
- [C07K 16/28](#) - SRCL-P1
- [C07K 16/28](#) - Stro-1
- [C07K 16/28](#) - T-cadherin, H-cadherin, truncate cadherin, cadherin 13
- [C07K 16/28](#) - TEM8, tumor endothelial marker 8, ANTXR1, anthrax toxin receptor 1

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/28](#) - Tetraspanin 10, TSPAN-10, TSN-10, TSN10, OSCP, oculospanin
- [C07K 16/28](#) - Tight junction protein 1, TJP1, TJP-1, ZO1, ZO-1, zonula occludin 1
- [C07K 16/28](#) - Tight junction protein 2, TJP2, TJP-2, ZO2, ZO-2, zonula occludin 2
- [C07K 16/28](#) - Tight junction protein 3, TJP3, TJP-3, ZO3, ZO-3, zonula occludin 3
- [C07K 16/28](#) - TLR12, Toll-like receptor 12
- [C07K 16/28](#) - TMEFF1, tomoregulin-1, tomoregulin 1, TR1, TR-1
- [C07K 16/28](#) - TMEFF2, tomoregulin-2, tomoregulin 2, TPEF, TENB2, HPP1, CT120.2, TMEFF-2, TR2, TR-2, transmembrane protein with EGF-like and two follistatin-like domains 2, hyperplastic polyposis protein
- [C07K 16/28](#) - TMEM216
- [C07K 16/28](#) - TRPV6, transient receptor potential cation channel subfamily V member 6, TrpV6, CaT-like, CaT-L, calcium transport protein 1, CaT1, epithelial calcium channel 2, ECAC2
- [C07K 16/28](#) - VLDLR, very low-density lipoprotein receptor
- [C07K 16/2803](#) - CD7, gp40
- [C07K 16/2803](#) - CD19, B4
- [C07K 16/2803](#) - CD22, BL-CAM, Lyb8 (mouse), Lyb-8 (mouse), siglec-2, sialic acid-binding Ig-related lectin 2
- [C07K 16/2803](#) - CD31, endocam, myelomonocytic differentiation antigen, PECAM-1, platelet endothelial cell adhesion molecule 1, (platelet) gpIIa
- [C07K 16/2803](#) - CD33, gp67, siglec-3, sialic acid-binding Ig-related lectin 3
- [C07K 16/2803](#) - CD47, gp42, GR63, IAP, OA3, 1D8
- [C07K 16/2803](#) - CD48, BCM1, blast-1, HuLy-M3, OX-45 (rat)
- [C07K 16/2803](#) - CD56, Leu19, Leu-19, L1CAM, L1-CAM, neural cell adhesion factor L1, NCAM, neural cell adhesion molecule, NKH1, NKH-1, Ng-CAM, 8D9
- [C07K 16/2803](#) - CD66
- [C07K 16/2803](#) - CD66a, BGP, biliary glycoprotein, CEACAM1, CEACAM-1, carcinoembryonic antigen-related cell adhesion molecule 1
- [C07K 16/2803](#) - CD66b, CD67, CGM6, NCA-95, p100, CEACAM8, CEACAM-8, carcinoembryonic antigen-related cell adhesion molecule 8
- [C07K 16/2803](#) - CD66c, NCA, NCA-50/90, CAECAM6, CEACAM-6, carcinoembryonic antigen-related cell adhesion molecule 6

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2803](#) - CD66d, CGM1, CEACAM3, CEACAM-3, carcinoembryonic antigen-related cell adhesion molecule 3
- [C07K 16/2803](#) - CD66f, PSG, pregnancy specific protein, SP-1, PSG1, PSG-1
- [C07K 16/2803](#) - CD79, B cell (antigen) receptor, BCR
- [C07K 16/2803](#) - CD79a, Igalpha, Ig alpha, MB1, mb-1, Iga
- [C07K 16/2803](#) - CD79b, Igbeta, Ig beta, MB2, mb-2, B29, Igb
- [C07K 16/2803](#) - CD83, HB15
- [C07K 16/2803](#) - CD85, LIR, GH1/75, VMP-55, LILR, leukocyte immunoglobulin-like receptor
- [C07K 16/2803](#) - CD85a, LIR3, LIR-3, LIR-PBM17, ILT5, LILRB3, Ig-like transcript 5, ILT-5
- [C07K 16/2803](#) - CD85b, ILT8, ILT-8
- [C07K 16/2803](#) - CD85c, LIR-8, LIR-PBMNEW
- [C07K 16/2803](#) - CD85d, LIR2, LIR-2, MIR10, ILT4, LIR-PBM8, LILRB2, ILT-4
- [C07K 16/2803](#) - CD85e, LIR4, LIR-4, LIR-PBM25, HM43, ILT6, ILT-6
- [C07K 16/2803](#) - CD85f, ILT11, ILT-11
- [C07K 16/2803](#) - CD85g, ILT7, ILT-7
- [C07K 16/2803](#) - CD85h, LIR7, LIR-7, LIR-PBMHH, ILT-1, ILT1, Ig-like transcript 1
- [C07K 16/2803](#) - CD85i, LIR6, LIR-6
- [C07K 16/2803](#) - CD85j, LIR-1, LIR-18A3, LIR-P3G2, ILT-2, ILT2, Ig-like transcript 2, MIR7, LILRB1
- [C07K 16/2803](#) - CD85k, LIR-5, LIR-PBM2, HM18, LILRB5, ILT3, ILT-3, Ig-like transcript 3
- [C07K 16/2803](#) - CD85l, ILT9, ILT-9, Ig-like transcript 9
- [C07K 16/2803](#) - CD85m, ILT10, ILT-10, Ig-like transcript 10
- [C07K 16/2803](#) - CD90, Thy1, Thy-1
- [C07K 16/2803](#) - CD96, TACTILE
- [C07K 16/2803](#) - CD100, semaphorin 4D, SEMA4D
- [C07K 16/2803](#) - CD101, BCP#4, GR14, V7
- [C07K 16/2803](#) - CD111, nectin 1, PRR1, PRR-1, poliovirus(-related) receptor 1
- [C07K 16/2803](#) - CD112, PRR2, PPR-2, poliovirus(-related) receptor 2, PVRL2, PVRL-2, poliovirus receptor-like 2, HVEB, herpesvirus entry protein B, herpesvirus entry mediator B, nectin 2
- [C07K 16/2803](#) - CD113, CDw113, nectin 3, PRR3, PRR-3, poliovirus(-related) receptor 3, PPR3, PVRR3, PVRL3, PVRL-3, poliovirus receptor-like 3

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2803](#) - CD117, c-kit, SCFR, SCF-R, SCF receptor, stem cell factor receptor
- [C07K 16/2803](#) - CD147, basigin, neurothelin, M6, emmprin, extracellular matrix metalloproteinase, TCSF, tumor collagenase stimulating factor, basoglin
- [C07K 16/2803](#) - CD150, CDw150, IPO-3, SLAM, surface lymphocyte activation molecule
- [C07K 16/2803](#) - CD158
- [C07K 16/2803](#) - CD158a, p58.1, p58.1 KIR, EB6, KIR2DL1
- [C07K 16/2803](#) - CD158b1, p58.2, p58.2 KIR, GL183, KIR2DL2
- [C07K 16/2803](#) - CD158b2, p58.3, p58.3 KIR, KIR2DL3
- [C07K 16/2803](#) - CD158c, KIRX, KIR X, KIR2DS6
- [C07K 16/2803](#) - CD158d, KIR2DL4
- [C07K 16/2803](#) - CD158e1, KIR3DL1
- [C07K 16/2803](#) - CD158e2, KIR3DS1
- [C07K 16/2803](#) - CD158f, KIR2DL5
- [C07K 16/2803](#) - CD158g, KIR2DS5
- [C07K 16/2803](#) - CD158h, p50.1, KIR2DS1
- [C07K 16/2803](#) - CD158i, p50.3, KIR2DS4
- [C07K 16/2803](#) - CD158j, p50.2, KIR2DS2
- [C07K 16/2803](#) - CD158k, p140, KIR3DL2
- [C07K 16/2803](#) - CD159, CDw159, NKB1, NKB-1, p70, NKG2A
- [C07K 16/2803](#) - CD160, CDw160, p140, NK1, NK28, BY55
- [C07K 16/2803](#) - CD166, ALCAM, activated leukocyte cell adhesion molecule, BEN (chicken), DM-GRASP (chicken), KG-CAM, neurolin (zebrafish), SC-1 (chicken)
- [C07K 16/2803](#) - CD169, Siglec-1, sialic acid-binding Ig-related lectin 1, sialoadhesin
- [C07K 16/2803](#) - CD170, Siglec-5, CD33-like 2, sialic acid-binding Ig-related lectin 5, OB-BP2
- [C07K 16/2803](#) - CD171, L1
- [C07K 16/2803](#) - CD172, SIRPs, signal regulatory proteins
- [C07K 16/2803](#) - CD172b, SIRPB1, SIRP beta-1, signal-regulatory protein beta 1, SIRP-B1
- [C07K 16/2803](#) - CD172g, SIRPB2, SIRP beta-2, signal-regulatory protein beta 2, SIRP gamma, SIRP-B2
- [C07K 16/2803](#) - CD179

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2803](#) - CD179a, IG1, immunoglobulin iota chain (or polypeptide), Vpre-B, VPBEB1, VPBEB-1, pre-B lymphocyte gene 1
- [C07K 16/2803](#) - CD179b, IGL5, immunoglobulin omega chain (or polypeptide), IGLL1, IGLL-1, immunoglobulin lambda-like polypeptide, 14.1, lambda 5
- [C07K 16/2803](#) - CD200, MRC OX2, OX2 (rat), OX-2 (rat)
- [C07K 16/2803](#) - CD223, LAG-3, lymphocyte activation gene 3
- [C07K 16/2803](#) - CD226, DNAM1, DNAM-1, DNAX accessory molecule 1, PTA1, PTA-1, platelet and T cell activation antigen 1, TLISA, T lineage-specific activation antigen 1
- [C07K 16/2803](#) - CD229, Ly9, Ly-9
- [C07K 16/2803](#) - CD244, 2B4
- [C07K 16/2803](#) - CD300, CLM
- [C07K 16/2803](#) - CD300a, CD300LA, CD300 (molecule)-like family member A, CMRF35H, CMRF-35H, CMRF35H9, CMRF-35-H9, IRC1, IRC2, Irp60, IgSF12, CLM8, CLM-8, CMRF35-like molecule 8
- [C07K 16/2803](#) - CD300b, CD300LB, CD300 (molecule)-like family member B, IREM3, IREM-3, immune receptor expressed by myeloid cells 3, CLM7, CLM-7, CMRF35-like molecule 7, TREM5, TREM-5, triggering receptor expressed on myeloid cells 5
- [C07K 16/2803](#) - CD300c, CD300LC, CD300 (molecule)-like family member C, CLM6, CLM-6, CMRF35-like molecule 6, CMRF35A, CMRF-35A, LIR, IgSF16, immunoglobulin superfamily member 16, CMRF-35A1, CMRF35, CMRF-35
- [C07K 16/2803](#) - CD300e, CD300LE, CD300 (molecule)-like family member E, IREM2, IREM-2, immune receptor expressed by myeloid cells, CLM2, CLM-2, CMRF35-like molecule 2, PIgR2, poly-Ig receptor 2
- [C07K 16/2803](#) - CD300f, CD300LF, CD300 (molecule)-like family member F, IREM1, IREM-1, immune receptor expressed by myeloid cells 1, CLM1, CLM-1, CMRF35-like molecule 1, IgSF13, immunoglobulin superfamily member 13, MAIR-5, MAIR-V, myeloid-associated immunoglobulin-like receptor 5, leukocyte mono-Ig-like receptor 3
- [C07K 16/2803](#) - CD300g, CD300LG, CD300 (molecule)-like family member G, CLM9, CLM-9, CMRF35-like molecule 9, TREM4, TREM-4, triggering receptor expressed on myeloid cells 4, NEPMUCIN
- [C07K 16/2803](#) - CD305, LAIR1, LAIR-1, leukocyte-associated Ig-like receptor 1
- [C07K 16/2803](#) - CD306, LAIR2, LAIR-2, leukocyte-associated Ig-like receptor 2

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2803](#) - CD315, CD9 partner 1, CD9P1, PTGFRN, prostaglandin F2 receptor negative regulator, FPRP, EWI-F, SMAP-6, FLJ11001, KIAA1436
- [C07K 16/2803](#) - CD316, EWI2, IgSF8, immunoglobulin superfamily member 8, PGRL, CD81P3, CD81 partner 3, KASP
- [C07K 16/2803](#) - CD319, SLAMF7, CRACC, SLAM family member 7, 19A, CS1, 19A24, CD2-like receptor activating cytotoxic cells, CD2 subset 1, LY9-like protein, FOAP-12, Ly9
- [C07K 16/2803](#) - CD321, JAM1, JAM-1, F11R, F11 receptor, KAT, JCAM, PAM-1, platelet adhesion molecule 1, junctional adhesion molecule 1
- [C07K 16/2803](#) - CD322, JAM2, JAM-2, VEJAM, PRO245, VE-JAM, vascular endothelial junction-associated molecule, junctional adhesion molecule 2
- [C07K 16/2803](#) - CD323, JAM3, JAM-3, junctional adhesion molecule 3
- [C07K 16/2803](#) - CD335, NKp46, NCR1, NCR-1, natural cytotoxicity triggering receptor 1, LY94, NK-p46, Ly-94 homolog
- [C07K 16/2803](#) - CD336, NKp44, NCR2, NCR-2, natural cytotoxicity triggering receptor 2, LY95, NK-p44, Ly-95 homolog
- [C07K 16/2803](#) - CD337, NKp30, NCR3, NCR-3, natural cytotoxicity triggering receptor 3, LY117, 1C7, NL-p30
- [C07K 16/2803](#) - CD352, SLAMF6, NTB-A, KAL.1, Ly108
- [C07K 16/2803](#) - CD353, SLAMF8, BLAME
- [C07K 16/2803](#) - CD354, TREM1, TREM-1, triggering receptor expressed in myeloid cells 1
- [C07K 16/2803](#) - A33, GPA33
- [C07K 16/2803](#) - A33-like 3
- [C07K 16/2803](#) - A34
- [C07K 16/2803](#) - AMIGO-2, amphoterin-induced protein 2
- [C07K 16/2803](#) - BTF, butyrophilin, BTN
- [C07K 16/2803](#) - BTN1
- [C07K 16/2803](#) - BTN2
- [C07K 16/2803](#) - BTN2A1
- [C07K 16/2803](#) - BTN2A2
- [C07K 16/2803](#) - BTN2A3
- [C07K 16/2803](#) - CADM-2, cell adhesion molecule 2
- [C07K 16/2803](#) - CADM-3, cell adhesion molecule 3
- [C07K 16/2803](#) - CADM-4, cell adhesion molecule 4
- [C07K 16/2803](#) - CAR, Coxsackie adenovirus receptor
- [C07K 16/2803](#) - C-CAM

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2803](#) - CD200R, CD200 receptor, OX-2R
- [C07K 16/2803](#) - CD200Ra, OX-2Ra
- [C07K 16/2803](#) - CD200Rb, OX-2Rb
- [C07K 16/2803](#) - CDO, cam-related gene down regulated by oncogenes
- [C07K 16/2803](#) - CHL1
- [C07K 16/2803](#) - contactin, neuro-1 antigen
- [C07K 16/2803](#) - CTXL, cortical thymocyte receptor-like protein
- [C07K 16/2803](#) - CXADR, Coxsackie and adenovirus receptor
- [C07K 16/2803](#) - DCC, deleted in colorectal carcinoma
- [C07K 16/2803](#) - EndoCAM, gp130
- [C07K 16/2803](#) - gp49B1
- [C07K 16/2803](#) - gpVI, glycoprotein VI, TANGO 268
- [C07K 16/2803](#) - HCTX
- [C07K 16/2803](#) - human LIG-1 homolog (HLIG-1)
- [C07K 16/2803](#) - IgSF4, immunoglobulin superfamily member 4, LDCAM, TSLC1, nectin-like 2, SynCAM, CADM-1, cell adhesion molecule 1
- [C07K 16/2803](#) - IgSF9, immunoglobulin superfamily member 9
- [C07K 16/2803](#) - JAM, junctional adhesion molecule
- [C07K 16/2803](#) - JAM-A
- [C07K 16/2803](#) - JAM-B
- [C07K 16/2803](#) - JAM-C
- [C07K 16/2803](#) - JAML, JAM-L, JAM-like
- [C07K 16/2803](#) - KIM-1, kidney injury molecule 1, TIM-1, HAVCR-1, hepatitis A virus cellular receptor
- [C07K 16/2803](#) - KIRHy, killer cell Ig-like receptor-like protein(s)
- [C07K 16/2803](#) - KIRREL, gp202, nephrin-like protein
- [C07K 16/2803](#) - LINGO-1, LRRN6, LRRN6A, FLJ14594, LERN1, MGC17422, UNQ201, Sp35
- [C07K 16/2803](#) - LIR-6A, LIR-PBM36-4
- [C07K 16/2803](#) - LIR-6B, LIR-PBM36-2
- [C07K 16/2803](#) - LILRB, PirB
- [C07K 16/2803](#) - Lisch-like
- [C07K 16/2803](#) - MadCAM-1, mucosal vascular addressin, mucosal addressin cell adhesion molecule
- [C07K 16/2803](#) - OMgp, oligodendrocyte myelin glycoprotein, MOgp, myelin oligodendrocyte glycoprotein
- [C07K 16/2803](#) - OB-CAM, opioid binding cell adhesion molecule

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2803](#) - Oscar, osteoclast-associated receptor
- [C07K 16/2803](#) - PILRalpha, PILR alpha, FDF03
- [C07K 16/2803](#) - PILRbeta, PILR beta
- [C07K 16/2803](#) - RAGE, receptor for advanced glycated end products
- [C07K 16/2803](#) - ROBO1, roundabout homolog 1, Slit2 receptor, DUTT1
- [C07K 16/2803](#) - ROBO2, roundabout homolog 2
- [C07K 16/2803](#) - ROBO3, roundabout homolog 3
- [C07K 16/2803](#) - ROBO4, roundabout homolog 4, axon guidance receptor (homolog) 4, ECSM4, magic roundabout, magic robo, MRB
- [C07K 16/2803](#) - ROR-1, ROR1, receptor tyrosine kinase orphan receptor 1
- [C07K 16/2803](#) - ROR-2, ROR2, receptor tyrosine kinase orphan receptor 2
- [C07K 16/2803](#) - siglec, sialic acid-binding Ig-related lectin
- [C07K 16/2803](#) - siglec-4, sialic acid-binding Ig-related lectin 4, MAG, myelin-associated glycoprotein
- [C07K 16/2803](#) - siglec -4b, sialic acid-binding Ig-related lectin 4b, SMP, Schwann cell myelin protein
- [C07K 16/2803](#) - siglec-6, sialic acid-binding Ig-related lectin 6, OB-BP1, CD33L
- [C07K 16/2803](#) - siglec-7, sialic acid-binding Ig-related lectin 7
- [C07K 16/2803](#) - siglec-8, sialic acid-binding Ig-related lectin 8
- [C07K 16/2803](#) - siglec-9, sialic acid-binding Ig-related lectin 9
- [C07K 16/2803](#) - siglec-10, sialic acid-binding Ig-related lectin 10
- [C07K 16/2803](#) - siglec-11, sialic acid-binding Ig-related lectin 11
- [C07K 16/2803](#) - siglec-12, sialic acid-binding Ig-related lectin 12
- [C07K 16/2803](#) - siglec-13, sialic acid-binding Ig-related lectin 13
- [C07K 16/2803](#) - siglec-14, sialic acid-binding Ig-related lectin 14
- [C07K 16/2803](#) - siglec-15, sialic acid-binding Ig-related lectin 15
- [C07K 16/2803](#) - SPEX, spleen expressed protein
- [C07K 16/2803](#) - TARM, T cell interacting receptor on myeloid cells
- [C07K 16/2803](#) - TIM-3, T cell immunoglobulin and mucin domain 3
- [C07K 16/2803](#) - TOSO, PIGRL
- [C07K 16/2803](#) - TREM1, TREM-1, triggering receptor expressed in myeloid cells 1
- [C07K 16/2803](#) - TREM2, TREM-2, triggering receptor expressed in myeloid cells 2
- [C07K 16/2803](#) - TREM3, TREM-3, triggering receptor expressed in myeloid cells 3

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2803](#) - TREM4, TREM-4, triggering receptor expressed in myeloid cells 4
- [C07K 16/2803](#) - TREM11, TREM-11, triggering receptor expressed in myeloid cells 11
- [C07K 16/2803](#) - TREML1, TREML-1, TLT1, TLT-1, TREM like 1
- [C07K 16/2803](#) - TREML2, TREML-2, TLT2, TLT-2, TREM like 2
- [C07K 16/2803](#) - TREML3, TREML-3, TLT3, TLT-3, TREM like 3
- [C07K 16/2803](#) - TREML4, TREML-4, TLT4, TLT-4, TREM like 4
- [C07K 16/2803](#) - UncB5, Unc-5 homolog B, netrin receptor
- [C07K 16/2803](#) - vaccinia virus B15 receptor
- [C07K 16/2806](#) - CD2, E-rosette receptor, LFA-2, lymphocyte function antigen 2, SRBC receptor, sheep red blood cell receptor, T11
- [C07K 16/2806](#) - CD2R, T11-3
- [C07K 16/2809](#) - CD3, TcR, CD3-TcR complex, TcR-CD3 complex, Ti, T3, Leu4, Leu-4
- [C07K 16/2809](#) - CD247, zeta chain, CD3 zeta chain
- [C07K 16/2812](#) - CD4, T4, Leu3, Leu-3, L3T4 (mouse), W3/25 (rat)
- [C07K 16/2815](#) - CD8, T8, Leu2, Leu-2, Lyt-2 (mouse), Lyt2/3 (mouse)
- [C07K 16/2815](#) - CD8a
- [C07K 16/2815](#) - CD8b
- [C07K 16/2818](#) - CD28, T44, Tp44
- [C07K 16/2818](#) - CD152, CTLA4, CTLA-4
- [C07K 16/2818](#) - CD272, BTLA, B and T lymphocyte attenuator, B and T lymphocyte associated
- [C07K 16/2818](#) - CD278, ICOS, inducible costimulator, AILIM, inducible T cell co-stimulator, MGC39850, CRP-1, CD28-related protein 1, CLP, CTLA-4-like protein
- [C07K 16/2818](#) - CD279, PD-1, programmed death 1, PDCD1, programmed (cell) death 1, SLEB2, hPD-1
- [C07K 16/2818](#) - Tim-3
- [C07K 16/2818](#) - zB7R1
- [C07K 16/2821](#) - ICAM molecules
- [C07K 16/2821](#) - CD50, CDw50, ICAM-3, ICAM-R, intercellular adhesion molecule 3
- [C07K 16/2821](#) - CD54, ICAM-1, intercellular adhesion molecule 1, rhinovirus receptor
- [C07K 16/2821](#) - CD102, ICAM-2, intercellular adhesion molecule 2

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2821](#) - CD242, ICAM-4, intercellular adhesion molecule 4
- [C07K 16/2821](#) - ICAM-5, telencephalin
- [C07K 16/2824](#) - CD58, LFA-3, lymphocyte function antigen 3
- [C07K 16/2827](#) - B7 molecules
- [C07K 16/2827](#) - CD80, B7-1, B7, BB1
- [C07K 16/2827](#) - CD86, B7-2, B70, BU63, FUN-1
- [C07K 16/2827](#) - CD273, B7-DC, PD-L2, B7DC, PDL2, Btdc, PDCD1LG2, PDCD1L2, programmed cell death 1 ligand 2, bA574F11.2
- [C07K 16/2827](#) - CD274, B7-H1, B7H1, PD-L1, PDL1, PDCD1LG1, PDCD1L1, programmed cell death 1 ligand 1
- [C07K 16/2827](#) - CD275, B7-H2, B7H2, B7h, B7RP-1, GL50, LICOS, ligand of inducible costimulator, ICOS-L, ICOSL, ICOS ligand, KIAA0653, inducible T cell co-stimulator ligand, B7RP1, B7-related protein 1
- [C07K 16/2827](#) - CD276, B7-H3, B7H3, 2Ig-B7-H3, B7RP2, B7RP-2
- [C07K 16/2827](#) - CD277, BTF5, BT3.1, BTN3A1, btyrophilin SF3 A1
- [C07K 16/2827](#) - BTN3
- [C07K 16/2827](#) - BT3.2, BTF4, BTN3A2
- [C07K 16/2827](#) - BT3.3, BTF3, BTN3A3
- [C07K 16/2827](#) - DC-HIL
- [C07K 16/2827](#) - 4Ig-B7-H3, 4Ig-B7H3 (also in [C07K 16/30](#))
- [C07K 16/2827](#) - B7-L1
- [C07K 16/2827](#) - B7-H4, B7H4, B7x, B7S1, B7-S1Ov064, ovr110, VTCN1
- [C07K 16/2827](#) - B7-H5, B7H5, VISTA
- [C07K 16/2827](#) - B7-H6, B7H6, NR3L1, NCR3LG1
- [C07K 16/2827](#) - HHLA2
- [C07K 16/2827](#) - BTF4
- [C07K 16/2827](#) - pNKp30
- [C07K 16/283](#) - CD16, Fc gamma receptor III, Fc gamma RIII, low affinity receptor for monomeric IgG, low affinity Fc gamma receptor, Leu11, Leu-11
- [C07K 16/283](#) - CD16a, Fc gamma RIIIA, Fc gamma RIIIA, Fc gamma receptor IIIA
- [C07K 16/283](#) - CD16b, Fc gamma RIIIB, Fc gamma RIIIB, Fc gamma receptor IIIB
- [C07K 16/283](#) - CD32, Fc gamma receptor II, Fc gamma RII, low affinity receptor for aggregated IgG, Fc gamma RII
- [C07K 16/283](#) - CD32A, Fc gamma receptor IIA, Fc gamma RIIa, Fc gamma RIIA

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/283](#) - CD32B, Fc gamma receptor IIB, Fc gamma RIIB, Fc gamma RIIB
- [C07K 16/283](#) - CD32C, Fc gamma receptor IIC, Fc gamma RIIC, Fc gamma RIIC
- [C07K 16/283](#) - CD64, Fc gamma receptor I, Fc gamma RI, high affinity receptor for IgG, high affinity Fc gamma receptor
- [C07K 16/283](#) - CD89, Fc alpha R, IgA receptor, receptor for IgA
- [C07K 16/283](#) - CD307, IRTA2, immunoglobulin superfamily receptor translocation associated 2, BXMAS1, FLJ00333, RP11-217A12.1, FcRH5, FcRH-5, IRTA-2
- [C07K 16/283](#) - Fc epsilon RI, Fc epsilon receptor I, Fc epsilon receptor, high affinity receptor for IgE
- [C07K 16/283](#) - IRTA1, IRTA-1, immune receptor translocation-associated 1, Fc receptor homolog 1, FcRH-4, immunoglobulin superfamily receptor translocation associated 1, FcRH4
- [C07K 16/283](#) - IRTA3, IRTA-3, immune receptor translocation-associated 3, Fc receptor homolog 3, FcRH-3, immunoglobulin superfamily receptor translocation associated 3, FcRH3
- [C07K 16/283](#) - IRTA4, IRTA-4, immune receptor translocation-associated 4, Fc receptor homolog 4, FcRH-2, immunoglobulin superfamily receptor translocation associated 4, FcRH2
- [C07K 16/283](#) - IRTA5, IRTA-5, immune receptor translocation-associated 5, Fc receptor homolog 5, FcRH-1, immunoglobulin superfamily receptor translocation associated 5, FcRH1
- [C07K 16/283](#) - IRTA6, IRTA-6, immune receptor translocation-associated 6, Fc receptor homolog 6, FcRH-6, immunoglobulin superfamily receptor translocation associated 6, FcRH6
- [C07K 16/283](#) - pIgR, poly-Ig receptor
- [C07K 16/2833](#) - CD1, T6
- [C07K 16/2833](#) - CD1a, R4, HTA1
- [C07K 16/2833](#) - CD1b, R1
- [C07K 16/2833](#) - CD1c, R7, M241
- [C07K 16/2833](#) - CD1d, R3
- [C07K 16/2833](#) - CD1e, R2
- [C07K 16/2833](#) - CD74, Ii, MHC class II invariant chain, MHC class II gamma chain
- [C07K 16/2833](#) - HFE

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2833](#) - MHC, major histocompatibility complex, HLA (human), H-2 (mouse)
- [C07K 16/2833](#) - MICA, MHC-I A chain-related protein
- [C07K 16/2833](#) - MICB, MHC-I B chain-related protein
- [C07K 16/2833](#) - MICC, MHC-I C chain-related protein
- [C07K 16/2833](#) - MICD, MHC-I D chain-related protein
- [C07K 16/2833](#) - MICE, MHC-I E chain-related protein
- [C07K 16/2833](#) - MPYS (in mice), MPHS (in man), MHC II associated protein
- [C07K 16/2833](#) - b2m, beta-2 microglobulin, thymotaxin
- [C07K 16/2836](#) - CD106, VCAM-1, INCAM-110
- [C07K 16/2839](#) - CD103, alphaM290, HML1, HML-1, human mucosal lymphocyte 1 antigen, integrin alphaE
- [C07K 16/2839](#) - CD104, beta4 integrin, reg receptor
- [C07K 16/2839](#) - LPAM-1, lymphocyte Peyer's patch adhesion molecule 1
- [C07K 16/2839](#) - pactolus
- [C07K 16/2842](#) - integrin beta1 (subunit-)containing molecule(s)
- [C07K 16/2842](#) - CD29
- [C07K 16/2842](#) - CD49
- [C07K 16/2842](#) - CD49a, CD49a/CD29, VLA-1, very late antigen 1, integrin alpha1beta1
- [C07K 16/2842](#) - CD49b, CD49b/CD29, VLA-2, very late antigen 2, ECMRII, ECMR-II, extracellular matrix receptor (type) II, (platelet) gpIa, (platelet) gpIa/IIa, integrin alpha2beta1
- [C07K 16/2842](#) - CD49c, CD49c/CD29, VLA-3, very late antigen 3, ECMRI, ECMR-I, extracellular matrix receptor (type) I, integrin alpha3beta1
- [C07K 16/2842](#) - CD49d, CD49d/CD29, VLA-4, very late antigen 4, integrin alpha4beta1
- [C07K 16/2842](#) - CD49e, CD49e/CD29, VLA-5, very late antigen 5, ECMRVI, ECMR-VI, extracellular matrix receptor (type) VI, (platelet) gpIc, (platelet) gpIc/IIa, integrin alpha5beta1, fibronectin receptor alpha chain
- [C07K 16/2842](#) - CD49f, CD49f/CD29, VLA-6, very late antigen 6, integrin alpha6beta1
- [C07K 16/2842](#) - LPAM-2, lymphocyte Peyer's patch adhesion molecule 2
- [C07K 16/2845](#) - integrin beta2 (subunit-)containing molecule(s)
- [C07K 16/2845](#) - CD11
- [C07K 16/2845](#) - CD11a, CD11a/CD18, LFA-1, lymphocyte function antigen 1, LeuCAMa, integrin alphaL

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2845](#) - CD11b, CD11b/CD18, CR3, C3biR, Mac-1, integrin alphaM
- [C07K 16/2845](#) - CD11c, CD11c/CD18, CR4, p150-95, integrin alphaX
- [C07K 16/2845](#) - CD18
- [C07K 16/2848](#) - integrin beta3 (subunit-)containing molecule(s)
- [C07K 16/2848](#) - CD41, CD41/CD61, (platelet) gpIIb, (platelet) gpIIb/gpIIIa, (platelet) GpIIb/IIIa
- [C07K 16/2848](#) - CD51, CD51/CD61 VNR, VN-R, vitronectin receptor
- [C07K 16/2848](#) - CD61, CD41/CD61, CD51/CD61, (platelet) gpIIIa, (platelet) gpIIb/IIIa
- [C07K 16/2851](#) - CD23, Fc epsilon RII, Fc epsilon receptor II, low affinity receptor for IgE, low affinity Fc epsilon receptor, Leu20, Leu-20, B6, BLAST 2
- [C07K 16/2851](#) - CD69, AIM, activation inducer molecule, EA1, EA-1, gp34/28, VEA (mouse), very early activation (mouse)
- [C07K 16/2851](#) - CD72, Lyb-2 (mouse)
- [C07K 16/2851](#) - CD94, kp43
- [C07K 16/2851](#) - CD159c, NKG2C, NKG2-C, KLRC2, killer cell lectin-like receptor subfamily C member 2,
- [C07K 16/2851](#) - CD161, NKRP1, NKR-P1A
- [C07K 16/2851](#) - CD167a, DDR1, discoidin domain receptor 1
- [C07K 16/2851](#) - CD205, DEC-205, DEC205, LY75
- [C07K 16/2851](#) - CD206, (macrophage) mannose receptor
- [C07K 16/2851](#) - CD207, langerin, CLEC4K
- [C07K 16/2851](#) - CD209, DC-SIGN, dendritic cell-specific ICAM-3 grabbing nonintegrin 1, DC-SIGN1, CLEC4L, CDSIGN
- [C07K 16/2851](#) - CD248, TEM1, tumor endothelial marker, endosialin, CD164L1, CD164 sialomucin-like 1
- [C07K 16/2851](#) - CD280, MRC2, MRC-2, mannose receptor C type 2, UPARAP, KIAA0709, ENDO180
- [C07K 16/2851](#) - CD299, DC-SIGNR, DC-SIGN related, CD209 antigen-like, probable mannose-binding C-type lectin, liver/lymph node-specific ICAM-3-grabbing nonintegrin 2, LSIGN, L-SIGN, DCSIGNR HP10347, DC-SIGN2, MGC47866, CD209L, C-type lectin domain family 4 member M, CLEC4M
- [C07K 16/2851](#) - CD301, CLEC10A, C-type lectin domain family 10 member A, C-type lectin superfamily member 14, HML2, CLECSF13, CLECSF14, MGL, HML
- [C07K 16/2851](#) - CD302, DCL-1, DCL1, BIMLEC, CLEC13A, KIAA0022, C-type lectin domain family 13 member A

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2851](#) - CD303, BDCA2, CLEC4C, C-type lectin domain family 4 member C, DLEC, HECL, CLECSF7, CLECSF11, PRO34150, blood dendritic cell antigen 2, dendritic cell lectin b
- [C07K 16/2851](#) - CD314, NKG2D, NKG2-D, KLR, KLRK1, killer cell lectin-like receptor subfamily K, D12S2489E, NK cell receptor D
- [C07K 16/2851](#) - CD327, CDw327, siglec6, diglec-6, sialic acid binding Ig-like lectin 6, CD33L, CD33 antigen-like 1, OBBP1, siglec-6
- [C07K 16/2851](#) - CD328, CDw328, siglec7, diglec-7, sialic acid binding Ig-like lectin 7, p75, QA79, AIRM1, D-siglec precursor, adhesion inhibitory receptor molecule 1, siglec-7
- [C07K 16/2851](#) - CD329, CDw329, siglec9, diglec-9, sialic acid binding Ig-like lectin 9, OBBP-like, OB binding protein, siglec-9
- [C07K 16/2851](#) - ASGR1, ASGR-1
- [C07K 16/2851](#) - ASGR2, ASGR-2, CLEC4H2
- [C07K 16/2851](#) - CLEC1
- [C07K 16/2851](#) - CLEC1A
- [C07K 16/2851](#) - CLEC1B, CLEC2
- [C07K 16/2851](#) - CLEC2A
- [C07K 16/2851](#) - CLEC2B
- [C07K 16/2851](#) - CLEC2D
- [C07K 16/2851](#) - CLEC2L
- [C07K 16/2851](#) - CLEC3A
- [C07K 16/2851](#) - CLEC3B
- [C07K 16/2851](#) - CLEC3O
- [C07K 16/2851](#) - CLEC3Q
- [C07K 16/2851](#) - CLEC4A, DCIR, dendritic cell immunoreceptor, LLIR, CLECSF6, DDB27
- [C07K 16/2851](#) - CLEC4D, CLEC6
- [C07K 16/2851](#) - CLEC4E, MINCLE
- [C07K 16/2851](#) - CLEC4F, KCLR
- [C07K 16/2851](#) - CLEC4G
- [C07K 16/2851](#) - CLEC5A, DVLR1, Dengue virus like receptor 1, MDL-1
- [C07K 16/2851](#) - CLEC6A, dectin-2, SDCMP, Schering dendritic cell membrane protein
- [C07K 16/2851](#) - CLEC7A, dectin-1
- [C07K 16/2851](#) - CLEC9A, DNGR1
- [C07K 16/2851](#) - CLEC11A

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2851](#) - CLEC12A, MICL
- [C07K 16/2851](#) - CLEC14A
- [C07K 16/2851](#) - CLL-1, CLL1, C-type lectin-like (family)
- [C07K 16/2851](#) - COLEC10
- [C07K 16/2851](#) - conglutinin
- [C07K 16/2851](#) - DCAL1
- [C07K 16/2851](#) - DDR2, DDR-2, discoidin domain receptor 2
- [C07K 16/2851](#) - DX1
- [C07K 16/2851](#) - FCER2
- [C07K 16/2851](#) - Galectin 1
- [C07K 16/2851](#) - Galectin 2
- [C07K 16/2851](#) - Galectin 3, MAC2, macrophage galactose-specific lectin 2, CBP-35, epsilon BP, L-29, carbohydrate binding protein 35, human IgE binding factor epsilon
- [C07K 16/2851](#) - Galectin 4
- [C07K 16/2851](#) - Galectin 5
- [C07K 16/2851](#) - Galectin 6
- [C07K 16/2851](#) - Galectin 7
- [C07K 16/2851](#) - Galectin 8
- [C07K 16/2851](#) - Galectin 9
- [C07K 16/2851](#) - Galectin 10
- [C07K 16/2851](#) - Galectin 11
- [C07K 16/2851](#) - Galectin 12
- [C07K 16/2851](#) - Galectin 13
- [C07K 16/2851](#) - Galectin 14
- [C07K 16/2851](#) - Galectin 15
- [C07K 16/2851](#) - KLRB1
- [C07K 16/2851](#) - LLT1, LLT-1, lectin-like transcript 1
- [C07K 16/2851](#) - MacropKLRF1hage antigen TMAH
- [C07K 16/2851](#) - MBL, mannose binding lectin, MBP, mannose binding protein
- [C07K 16/2851](#) - MRC1, MRC-1
- [C07K 16/2851](#) - MRC1L1
- [C07K 16/2851](#) - OLR1, OLR-1
- [C07K 16/2851](#) - PLA2R1
- [C07K 16/2854](#) - selectins
- [C07K 16/2854](#) - CD62, selectin

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2854](#) - CD62E, E-selectin, ELAM-1, endothelial leukocyte adhesion molecule 1, LECAM-2, LEC-CAM-2
- [C07K 16/2854](#) - CD62L, L-selectin, LAM-1, Leu8, Leu-8, LECAM-1, LEC-CAM-1, TQ1, TQ-1, MEL-14, DREG, peripheral lymph node homing receptor, pnHR, gp100MEL, gp110MEL
- [C07K 16/2854](#) - CD62P, P-selectin, LECAM-3, LEC-CAM-3, PADGEM, gmp140, GMP-140, platelet activation dependent granule external membrane
- [C07K 16/2857](#) - HIF, hypoxia-inducible factor
- [C07K 16/2857](#) - Nurr1, NR4A2
- [C07K 16/2857](#) - PARR alpha, peroxisome proliferator activated receptor alpha
- [C07K 16/2857](#) - PARR delta/beta, peroxisome proliferator activated receptor delta/beta
- [C07K 16/2857](#) - PARR gamma, peroxisome proliferator activated receptor gamma
- [C07K 16/2857](#) - PXR
- [C07K 16/2857](#) - ROR gamma t, retinoic acid-related orphan receptor
- [C07K 16/286](#) - Adrenoreceptors, adrenergic receptors, adrenoceptors, epinephrine receptors, adrenaline receptors, norepinephrine receptors, noradrenaline receptors (also in [C07K 16/2869](#))
- [C07K 16/286](#) - Alpha-1 adrenoreceptor, alpha-1 adrenergic receptor, alpha-1 adrenoceptor, A1AR, alpha-1 AR, ADRA1R, ALPHA1AR (also in [C07K 16/2869](#))
- [C07K 16/286](#) - Alpha-2 adrenoreceptor, alpha-2 adrenergic receptor, alpha-2 adrenoceptor, A2AR, alpha-2 AR, ADRA2R, ALPHA2AR (also in [C07K 16/2869](#))
- [C07K 16/286](#) - Beta-1 adrenoreceptor, beta-1 adrenergic receptor, beta-1 adrenoceptor, B1AR, beta-1 AR, ADRB1R, BETA1AR, RHR (also in [C07K 16/2869](#))
- [C07K 16/286](#) - Beta-2 adrenoreceptor, beta-2 adrenergic receptor, beta-2 adrenoceptor, B2AR, beta-2 AR, ADRB2R, BETA2AR (also in [C07K 16/2869](#))
- [C07K 16/286](#) - Acetylcholine receptor
- [C07K 16/286](#) - Neuromediator receptors
- [C07K 16/286](#) - BGT-1
- [C07K 16/286](#) - Dopamine receptor
- [C07K 16/286](#) - GABA receptor subtype A, GABAAR, gamma aminobutyric acid receptor subtype A
- [C07K 16/286](#) - NK1, tachykinin NK1 receptor

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/286](#) - NK2, tachykinin NK2 receptor
- [C07K 16/286](#) - NK3, tachykinin NK3 receptor
- [C07K 16/286](#) - NMDAR, M-methyl-D-aspartate receptor
- [C07K 16/286](#) - NMUR1, neuromedin U receptor 1, FM-3, gpr66, G-protein coupled receptor 66
- [C07K 16/286](#) - NMUR2, neuromedin U receptor 2, FM-4
- [C07K 16/286](#) - NR1
- [C07K 16/286](#) - NR2
- [C07K 16/286](#) - NR2A
- [C07K 16/286](#) - NR2B
- [C07K 16/286](#) - NR2C
- [C07K 16/286](#) - NR2D
- [C07K 16/286](#) - NR3
- [C07K 16/286](#) - Serotonin receptor
- [C07K 16/286](#) - SorLA, sorting protein-related receptor, LR11
- [C07K 16/286](#) - SorCS1
- [C07K 16/286](#) - SorCS2
- [C07K 16/286](#) - SorCS3
- [C07K 16/286](#) - Sortilin, NTR3, NTR-3, neurotensin receptor 3, glycoprotein 95, gp95
- [C07K 16/2863](#) - growth factor receptors
- [C07K 16/2863](#) - CD135, FLT3, flt-3, flk-2 (mouse), STK-1
- [C07K 16/2863](#) - CD140, PDGFR
- [C07K 16/2863](#) - CD140a, PDGFR alpha, platelet derived growth factor receptor alpha
- [C07K 16/2863](#) - CD140b, PDGFR beta, platelet derived growth factor receptor beta
- [C07K 16/2863](#) - CD202b, Tek, Tie2
- [C07K 16/2863](#) - CD221, IGF1R, IGF1-R, insulin-like growth factor 1 receptor, insulin-like growth factor I receptor, IGFI-R
- [C07K 16/2863](#) - CD222, CIMPR, CI-MPR, M6PR, M6P-R, mannose-6 phosphate receptor, IGF2R, IGF2-R, insulin-like growth factor 2 receptor, IFGIIR, IGFI-R, insulin-like growth factor II receptor, MPRI
- [C07K 16/2863](#) - CD292, BMPR1A, bone morphogenetic protein receptor type IA, ALK3, ALK-3, ACVRLK3, activin A receptor type II-like kinase 3
- [C07K 16/2863](#) - CD293, CDw293, BMPR1B, bone morphogenetic protein receptor type IB, ALK6, ALK-6, serine/threonine receptor kinase

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2863](#) - CD304, BDCA4, NRP1, NRP-1, npn-1, neuropilin 1, VEGF165R
- [C07K 16/2863](#) - CD309, KDR, kinase insert domain receptor, FLK1 (mouse), flk-1 (mouse), fetal liver kinase 1 (mouse), VEGFR2, VEGFR-2, VEGF receptor 2, vascular endothelial growth factor receptor 2
- [C07K 16/2863](#) - CD331, FGFR1, fibroblast growth factor receptor 1, heparin-binding FGF receptor, basic FGF receptor, FLG protein, CEK, FLT2, flt-2, KAL2, BFGFR, C-FGR, N-SAM
- [C07K 16/2863](#) - CD332, FGFR2, fibroblast growth factor receptor 2, keratinocyte growth factor receptor, BEK, JWS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, K-SAM
- [C07K 16/2863](#) - CD333, FGFR3, fibroblast growth factor receptor 3, ACH, CEK2, TK4, HSGFR3EX
- [C07K 16/2863](#) - CD334, FGFR4, fibroblast growth factor receptor 4, TKF, JTK2, MGC20292
- [C07K 16/2863](#) - Adrenomedullin receptor, CLR, RAMP2, RAMP3
- [C07K 16/2863](#) - Activin receptor, ActR
- [C07K 16/2863](#) - Angiogenin receptor
- [C07K 16/2863](#) - Axl
- [C07K 16/2863](#) - Boc, bioregional Cdon-binding protein
- [C07K 16/2863](#) - Boi, brother of Ihog
- [C07K 16/2863](#) - EGFR, EGF-R, EGFR1, EGFR-1, EGF receptor, EGF receptor 1, epidermal growth factor receptor, epidermal growth factor receptor 1, urogastrone receptor, Her1, ErbB1, ErbB-1
- [C07K 16/2863](#) - EPOR, EPO-R, EPO receptor, erythropoietin receptor
- [C07K 16/2863](#) - ERRP, EGF receptor-related protein
- [C07K 16/2863](#) - FGFR5, fibroblast growth factor receptor 5
- [C07K 16/2863](#) - Frizzled (receptors), FZD
- [C07K 16/2863](#) - FZD-1, FZD1, Frizzled 1
- [C07K 16/2863](#) - FZD-2, FZD2, Frizzled 2
- [C07K 16/2863](#) - FZD-3, FZD3, Frizzled 3
- [C07K 16/2863](#) - FZD-4, FZD4, Frizzled 4
- [C07K 16/2863](#) - FZD-5, FZD5, Frizzled 5
- [C07K 16/2863](#) - FZD-6, FZD6, Frizzled 6
- [C07K 16/2863](#) - FZD-7, FZD7, Frizzled 7
- [C07K 16/2863](#) - FZD-8, FZD8, Frizzled 8
- [C07K 16/2863](#) - FZD-9, FZD9, Frizzled 9

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2863](#) - FZD-10, FZD10, Frizzled 10
- [C07K 16/2863](#) - Gasl, growth arrest-specific 1 (protein)
- [C07K 16/2863](#) - GFR, glial cell line-derived neurotrophic factor family receptor
- [C07K 16/2863](#) - GFRalpha1, GFRA1, GDNF receptor
- [C07K 16/2863](#) - GFRalpha2, GFRA2, neurturin receptor
- [C07K 16/2863](#) - GFRalpha3, GFRA3, artemin receptor
- [C07K 16/2863](#) - GFRalpha4, GFRA4, persephin receptor
- [C07K 16/2863](#) - GRP73a
- [C07K 16/2863](#) - GRP73b
- [C07K 16/2863](#) - Heregulin receptor
- [C07K 16/2863](#) - HGFR, HGF-R, HGF receptor, c-met, hepatocyte growth factor receptor
- [C07K 16/2863](#) - Hip, Hhip1, hedgehog-interacting protein
- [C07K 16/2863](#) - Ihog, interference hedgehog
- [C07K 16/2863](#) - Mer
- [C07K 16/2863](#) - MSPR, MSP receptor, macrophage stimulating protein receptor, RON
- [C07K 16/2863](#) - Neuregulin receptor
- [C07K 16/2863](#) - Neuropilin 2, npn-2, nrp-2
- [C07K 16/2863](#) - Nogo receptor 1, Nogo receptor, NogoR, NogoR-1, NgR, NgR-1
- [C07K 16/2863](#) - Osteogenin receptor
- [C07K 16/2863](#) - Patched, Ptch
- [C07K 16/2863](#) - PCDGFR, PCDGF receptor, gp88 receptor, PC cell derived growth factor receptor, Rse, Sky, rGP88, Tyro3, Etk2, Tif
- [C07K 16/2863](#) - RET
- [C07K 16/2863](#) - Smoothened, Smo
- [C07K 16/2863](#) - TGFR, TGF-R, TGF receptor, transforming growth factor receptor
- [C07K 16/2863](#) - Tie1
- [C07K 16/2863](#) - TrkA
- [C07K 16/2863](#) - TrkB
- [C07K 16/2863](#) - TrkC
- [C07K 16/2863](#) - VEGFR1, VEGFR-1, VEGF receptor 1, vascular endothelial growth factor receptor 1, FLT1 (mouse), flt-1 (mouse)
- [C07K 16/2863](#) - VEGFR3, VEGFR-3, VEGF receptor 3, vascular endothelial growth factor receptor 3, FLT4, flt-4

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2863](#) - ZAQ, EG-VEGF receptor
- [C07K 16/2863](#) - I1E
- [C07K 16/2866](#) - chemokine en cytokine receptors
- [C07K 16/2866](#) - CD25, Tac, IL-2R, IL-2Ralpha, IL-2R alpha (chain), IL-2 receptor alpha (chain), interleukin-2 receptor alpha (chain), TCGFR, TCGF-R, TCGF receptor, T cell growth factor receptor
- [C07K 16/2866](#) - CD110, MPL, TPOR, TPO-R, TPO receptor, thrombopoietin receptor
- [C07K 16/2866](#) - CD114, G-CSFR, G-CSF-R, G-CSF receptor, granulocyte colony-stimulating factor receptor, CSF3R, CSF-3R
- [C07K 16/2866](#) - CD115, M-CSFR, M-CSF-R, M-CSF receptor, macrophage colony-stimulating factor receptor, CSF1R, CSF-1R, c-fms
- [C07K 16/2866](#) - CD116, GM-CSFR, GM-CSF-R, GM-CSF receptor, granulocyte macrophage colony-stimulating factor receptor
- [C07K 16/2866](#) - CD118, LIFR, leukemia inhibitory factor receptor
- [C07K 16/2866](#) - CD119, CDw119, IFNgR, IFN-gamma receptor, interferon gamma receptor, IFNGR
- [C07K 16/2866](#) - CD121a, IL-1R type 1, IL-1 receptor type 1, interleukin-1 receptor type 1
- [C07K 16/2866](#) - CD121b, IL-1R type 2, IL-1 receptor type 2, interleukin-1 receptor type 2
- [C07K 16/2866](#) - CD122, IL-2R beta, IL-2R beta (chain), IL-2 receptor beta (chain), interleukin-2 receptor beta (chain)
- [C07K 16/2866](#) - CD123, IL-3Ralpha, IL-3R alpha (chain), IL-3 receptor alpha (chain), interleukin-3 receptor alpha (chain), CDw123
- [C07K 16/2866](#) - CD124, IL-4R, IL-4 receptor, interleukin-4 receptor
- [C07K 16/2866](#) - CD125, CDw125, IL-5Ralpha, IL-5R alpha (chain), IL-5 receptor alpha (chain), interleukin-5 receptor alpha (chain)
- [C07K 16/2866](#) - CD126, IL-6R, IL-6 receptor, interleukin-6 receptor
- [C07K 16/2866](#) - CD127, IL-7R, IL-7 receptor, interleukin-7 receptor, IL-7R alpha, IL-7R alpha (chain), IL-7 receptor alpha (chain), interleukin-7 receptor alpha (chain)
- [C07K 16/2866](#) - CDw128
- [C07K 16/2866](#) - CD129, IL-9R, IL-9 receptor, interleukin-9 receptor
- [C07K 16/2866](#) - CD130, gp130
- [C07K 16/2866](#) - CD131, CDw131, common beta chain, common cytokine receptor beta chain

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2866](#) - CD132, common gamma chain, common cytokine receptor gamma chain
- [C07K 16/2866](#) - CD181, CD128a, CDw128a, CXCR1, chemokine (type) CXC receptor 1, IL-8RA, IL-8Ralpha, IL-8 receptor A, interleukin-8 receptor A, interleukin-8 receptor alpha
- [C07K 16/2866](#) - CD182, CD128b, CDw128b, CXCR2, chemokine (type) CXC receptor 2, IL-8RB, IL-8Rbeta, IL-8 receptor B, interleukin-8 receptor B, interleukin-8 receptor beta
- [C07K 16/2866](#) - CD183, CXCR3, chemokine (type) CXC receptor 3
- [C07K 16/2866](#) - CD184, CXCR4, chemokine (type) CXC receptor 4, fusin, HUMSTR, LESTR
- [C07K 16/2866](#) - CD185, CXCR5, chemokine (type) CXC receptor 5, BLR1, BLR-1, Burkitt lymphoma receptor 1, MDR15
- [C07K 16/2866](#) - CD186, CDw186, CXCR6, chemokine (type) CXC receptor 6, BONZO, STRL33, TYMSTR
- [C07K 16/2866](#) - CD191, CCR1, chemokine (type) CC receptor 1, CKR-1, CC-CKR1, CMKBR1
- [C07K 16/2866](#) - CD192, CCR2, chemokine (type) CC receptor 2, CKR-2, CC-CKR2, MPC-1-R, MCP-1R, MCP-1 receptor, CCR2A, CCR2B, CKR2A, CKR2B, CMKBR2
- [C07K 16/2866](#) - CD193, CCR3, chemokine (type) CC receptor 3, CKR-3, CC-CKR3, CMKBR3
- [C07K 16/2866](#) - CD194, CCR4, chemokine (type) CC receptor 4, CKR-4, CC-CKR4, CMKBR4
- [C07K 16/2866](#) - CD195, CCR5, chemokine (type) CC receptor 5, CKR-5, CC-CKR5, CMKBR5
- [C07K 16/2866](#) - CD196, CCR6, chemokine (type) CC receptor 6, CKR-6, CC-CKR6, CMKBR6, BN-1, DCR2, CKRL3, DRY-6, GPR29, GPRCY4, GPR-CY4, STRL22, CKR-L3, LARC receptor
- [C07K 16/2866](#) - CD197, CDw197, CCR7, chemokine (type) CC receptor 7, CKR-7, CC-CKR7, CMBKR7
- [C07K 16/2866](#) - CD198, CDw198, CCR8, chemokine (type) CC receptor 8, CKR-8, CC-CKR8, CMBKR8, CY6, TER1, CKRL1, CKR-L1, GPR-CY6, CMKBRL2
- [C07K 16/2866](#) - CD199, CDw199, CCR9, chemokine (type) CC receptor 9, CKR-9, CC-CKR9, CMBKR9, GPR28, GPR-9-6
- [C07K 16/2866](#) - CD210, CDw210, IL-10R, IL-10 receptor, interleukin-10 receptor

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2866](#) - CD212, IL-12Rbeta1, IL-12 receptor beta 1, interleukin-12 receptor beta 1
- [C07K 16/2866](#) - CD213a1, IL-13R alpha 1, interleukin-13 receptor alpha 1
- [C07K 16/2866](#) - CD213a2, IL-13R alpha 2, interleukin-13 receptor alpha 2
- [C07K 16/2866](#) - CD217, IL-17R, IL-17 receptor, interleukin-17 receptor, zcytor14
- [C07K 16/2866](#) - CD218a, CDw218A, IL-18RA, IL-18R alpha, interleukin-18 receptor 1, interleukin-18 receptor alpha, IL1RRP, IL-1Rrp
- [C07K 16/2866](#) - CD218b, CDw218B, IL-18RB, IL-18R beta, interleukin-18 receptor beta, interleukin-18 receptor accessory protein, ACPL, IL18RAP
- [C07K 16/2866](#) - chemerin R, chemerin receptor, dez, CMKLR1, CMKLR-1, chemokine-like receptor 1
- [C07K 16/2866](#) - EphA1, ephrin receptor A1
- [C07K 16/2866](#) - EphA2, ephrin receptor A2
- [C07K 16/2866](#) - EphA3a, ephrin receptor A3a
- [C07K 16/2866](#) - EphA3b, ephrin receptor A3b
- [C07K 16/2866](#) - EphA4, ephrin receptor A4
- [C07K 16/2866](#) - EphA5a, ephrin receptor A5a
- [C07K 16/2866](#) - EphA5b, ephrin receptor A5b
- [C07K 16/2866](#) - EphA6, ephrin receptor A6
- [C07K 16/2866](#) - EphA7, ephrin receptor A7
- [C07K 16/2866](#) - EphA8, ephrin receptor A8
- [C07K 16/2866](#) - EphA9, ephrin receptor A9
- [C07K 16/2866](#) - EphA10, ephrin receptor A10
- [C07K 16/2866](#) - EphB1, ephrin receptor B1, Elk, Cek6, Net, Hek6
- [C07K 16/2866](#) - EphB2, ephrin receptor 2, Cek5, Nuk, Erk, Qek5, Tyro5, Sek3, Hek5, Drt
- [C07K 16/2866](#) - EphB2a, ephrin receptor B2a
- [C07K 16/2866](#) - EphB2b, ephrin receptor B2b
- [C07K 16/2866](#) - EphB3, ephrin receptor B3, Cek10, Hek2, Mdk5, Tyro6, Sek4, Hek4, Mek4
- [C07K 16/2866](#) - EphB4, ephrin receptor B4, Htk, Myk1, Mdk2, Tyro11, hepatoma transmembrane kinase (also in [C07K 16/30](#))
- [C07K 16/2866](#) - EphB5, ephrin receptor B5, Cek9, Hek9
- [C07K 16/2866](#) - EphB6, ephrin receptor B6, Mep
- [C07K 16/2866](#) - Hek7, Cek7
- [C07K 16/2866](#) - Hek8, Cek8

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2866](#) - Hek11
- [C07K 16/2866](#) - IFNAR, interferon alpha receptor
- [C07K 16/2866](#) - IFNAR-1, interferon alpha receptor 1
- [C07K 16/2866](#) - IFNAR-2, interferon alpha receptor 2
- [C07K 16/2866](#) - IL-1RAP, IL1RAP, IL-1RAcP, IL1R3, c3orf13, IL-1 receptor accessory protein
- [C07K 16/2866](#) - IL-11R, IL-11 receptor, interleukin-11 receptor
- [C07K 16/2866](#) - IL-14R, IL-14 receptor, interleukin-14 receptor
- [C07K 16/2866](#) - IL-15R, IL-15 receptor, interleukin-15 receptor
- [C07K 16/2866](#) - IL-16R, IL-16 receptor, interleukin-16 receptor
- [C07K 16/2866](#) - IL-17FR, IL-17F receptor
- [C07K 16/2866](#) - IL-17R, IL-17 receptor, interleukin-17 receptor, IL-17RA, IL-17 receptor A, interleukin-17 receptor A
- [C07K 16/2866](#) - IL-17RB, IL-17 receptor B, interleukin-17 receptor B
- [C07K 16/2866](#) - IL-17RC, IL-17 receptor C, interleukin-17 receptor C
- [C07K 16/2866](#) - IL-17RD, IL-17 receptor D, interleukin-17 receptor D
- [C07K 16/2866](#) - IL-17RE, IL-17 receptor E, interleukin-17 receptor E
- [C07K 16/2866](#) - IL-17RF, IL-17 receptor F, interleukin-17 receptor F
- [C07K 16/2866](#) - IL-19R, IL-19 receptor, interleukin-19 receptor
- [C07K 16/2866](#) - IL-20R, IL-20 receptor, interleukin-20 receptor
- [C07K 16/2866](#) - IL-21R, IL-21 receptor, interleukin-20 receptor, MU-1
- [C07K 16/2866](#) - IL-22RA, IL-22 receptor alpha, interleukin-22 receptor alpha, zcytor11
- [C07K 16/2866](#) - IL-23R, IL-23 receptor, interleukin-23 receptor, DCRS5, DNAX cytokine receptor subunit 5
- [C07K 16/2866](#) - IL-27R, IL-27 receptor, interleukin-27 receptor, TCCR
- [C07K 16/2866](#) - IL-27RA, WXS-1, IL-27 receptor alpha, interleukin 27 receptor alpha
- [C07K 16/2866](#) - IL-28R, IL-28 receptor, interleukin-28 receptor
- [C07K 16/2866](#) - IL-31RA, IL-31 receptor A, NR10, cytokine receptor nr. 10, CRL, CRL3, GLM-R, GPL, MGC125346, PRO21384, cytokine receptor-like 3, WAP5, whey acidic protein 5
- [C07K 16/2866](#) - IL-33R, IL-33 receptor, interleukin-33 receptor, ILRL1, ST2, T1/ST2, Fit-1, DER4, DER-4
- [C07K 16/2866](#) - L-CCR, LPS-inducible CC chemokine receptor
- [C07K 16/2866](#) - TPOR, TPO-R, TPO receptor, thrombopoietin receptor, Mp1
- [C07K 16/2866](#) - WSX receptor

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2866](#) - zalpha11
- [C07K 16/2869](#) - hormone receptors
- [C07K 16/2869](#) - CD220, insulin receptor
- [C07K 16/2869](#) - CD295, LEPR, leptin receptor
- [C07K 16/2869](#) - Adrenoreceptors, adrenergic receptors, adrenoceptors, epinephrine receptors, adrenaline receptors, norepinephrine receptors, noradrenaline receptors (also in [C07K 16/286](#))
- [C07K 16/2869](#) - Alarin receptor
- [C07K 16/2869](#) - Alpha-1 adrenoreceptor, alpha-1 adrenergic receptor, alpha-1 adrenoceptor, A1AR, alpha-1 AR, ADRA1R, ALPHA1AR (also in [C07K 16/286](#))
- [C07K 16/2869](#) - Alpha-2 adrenoreceptor, alpha-2 adrenergic receptor, alpha-2 adrenoceptor, A2AR, alpha-2 AR, ADRA2R, ALPHA2AR (also in [C07K 16/286](#))
- [C07K 16/2869](#) - Androgen receptor, AR
- [C07K 16/2869](#) - Angiotensin-II type-1 receptor, AT1
- [C07K 16/2869](#) - Angiotensin-II type-2 receptor, AT2
- [C07K 16/2869](#) - Anti-Müllerian hormone type II receptor, AMH type II receptor, AMH receptor type II, AMHIIR, AMHRII, MISIIR, MISRII, MIFIIR, MIFRII, AMHR-II, AMH-RII, MISR-II, MIS-RII, MIFR-II, MIF-RII
- [C07K 16/2869](#) - Apelin receptor, AGTRIA, APJ
- [C07K 16/2869](#) - Apelin receptor
- [C07K 16/2869](#) - Atrial natriuretic factor complex
- [C07K 16/2869](#) - Atriopeptin receptor
- [C07K 16/2869](#) - Atrial natriuretic peptide receptor, ANP receptor
- [C07K 16/2869](#) - Beta-1 adrenoreceptor, beta-1 adrenergic receptor, beta-1 adrenoceptor, B1AR, beta-1 AR, ADRB1R, BETA1AR, RHR (also in [C07K 16/286](#))
- [C07K 16/2869](#) - Beta-2 adrenoreceptor, beta-2 adrenergic receptor, beta-2 adrenoceptor, B2AR, beta-2 AR, ADRB2R, BETA2AR (also in [C07K 16/286](#))
- [C07K 16/2869](#) - Bombesin receptor
- [C07K 16/2869](#) - Calcitonin receptor
- [C07K 16/2869](#) - Calcitonin gene-related peptide receptor
- [C07K 16/2869](#) - Cardionatin receptor
- [C07K 16/2869](#) - Cardiodilatin receptor
- [C07K 16/2869](#) - Cholecystokinin receptor, CCK receptor
- [C07K 16/2869](#) - Chorionic gonadotropin receptor, HCG receptor
- [C07K 16/2869](#) - Chorionic somatomammotropin receptor
- [C07K 16/2869](#) - Corticotropin receptor

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2869](#) - Corticotropin releasing factor receptor, CRF receptor, urotensin receptor
- [C07K 16/2869](#) - CRF1R, corticotropin-releasing factor 1 receptor
- [C07K 16/2869](#) - CRF2R, corticotropin-releasing factor 2 receptor
- [C07K 16/2869](#) - Endorphin receptor
- [C07K 16/2869](#) - Endothelin receptor
- [C07K 16/2869](#) - Enkephalin receptor
- [C07K 16/2869](#) - Follicle-stimulating hormone receptor, FSH receptor
- [C07K 16/2869](#) - Galanin receptor, GAL receptor
- [C07K 16/2869](#) - Galanin-like peptide receptor, GALP receptor
- [C07K 16/2869](#) - Gastrin receptor
- [C07K 16/2869](#) - Gastrin releasing peptide receptor
- [C07K 16/2869](#) - Ghrelin receptor
- [C07K 16/2869](#) - GIP receptor, gastric inhibitory polypeptide receptor
- [C07K 16/2869](#) - Glucagon receptor
- [C07K 16/2869](#) - GLP-1 receptor, glucagon-like peptide 1 receptor, GLP1R, GLP-1R
- [C07K 16/2869](#) - GLP-2 receptor, glucagon-like peptide 2 receptor, GLP2R, GLP-2R
- [C07K 16/2869](#) - Growth hormone receptor, GH receptor, somatotropin receptor
- [C07K 16/2869](#) - Growth hormone releasing factor receptor, GHRF receptor
- [C07K 16/2869](#) - Lipotropin receptor
- [C07K 16/2869](#) - Luteinising hormone receptor, LH receptor
- [C07K 16/2869](#) - Melanocortin 1 receptor, MC1R, MCR1
- [C07K 16/2869](#) - Melanocortin 2 receptor, MC2R, MCR2
- [C07K 16/2869](#) - Melanocortin 3 receptor, MC3R, MCR3
- [C07K 16/2869](#) - Melanocortin 4 receptor, MC4R, MCR4
- [C07K 16/2869](#) - Melanocortin 5 receptor, MC5R, MCR5
- [C07K 16/2869](#) - Melanocyte stimulating hormone receptor, MSH receptor
- [C07K 16/2869](#) - Melanotropin receptor
- [C07K 16/2869](#) - Motilin receptor
- [C07K 16/2869](#) - Orphan glycoprotein hormone receptor, OGH receptor
- [C07K 16/2869](#) - Parathyroid hormone receptor, parathormone receptor
- [C07K 16/2869](#) - Parathyroid hormone related peptide receptor
- [C07K 16/2869](#) - Prolactin receptor
- [C07K 16/2869](#) - Prostaglandin receptors
- [C07K 16/2869](#) - Prostaglandin E2 receptor, PGE2 receptor, PGE2R

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2869](#) - Relaxin receptor
- [C07K 16/2869](#) - Salusin alpha receptor
- [C07K 16/2869](#) - Salusin beta receptor
- [C07K 16/2869](#) - Secretin receptor
- [C07K 16/2869](#) - Serotonin receptor
- [C07K 16/2869](#) - Somatostatin receptor
- [C07K 16/2869](#) - Substance P receptor
- [C07K 16/2869](#) - TFF3 receptor
- [C07K 16/2869](#) - Thymopoietin receptor
- [C07K 16/2869](#) - Thymosin receptor
- [C07K 16/2869](#) - Thyroid stimulating hormone receptor, TSH receptor
- [C07K 16/2869](#) - Vasoactive intestinal contractor receptor, VIC receptor
- [C07K 16/2869](#) - Vasoactive intestinal peptide receptor 1, VIP receptor, FLJ41949, HVR1 II, PACAP-R-2, RCD1, RDC1, VAPC1, VIP-R1, VIPR, VIRG, VPAC1, VPCAP1R
- [C07K 16/2872](#) - CD230, prion protein, PrP, PrPsc
- [C07K 16/2875](#) - NGF/TNF (ligand) superfamily
- [C07K 16/2875](#) - CD70, CD27L, CD27-L, CD27 ligand, Ki-24, TNFSF7, tumor necrosis factor (ligand) superfamily member 7
- [C07K 16/2875](#) - CD153, CD30L, CD30-L, CD30 ligand, TNFSF8, tumor necrosis factor superfamily member 8
- [C07K 16/2875](#) - CD154, CD40L, CD40-L, CD40 ligand, CD40CR, gp39, T-BAM, 5c8, TRAP, TNFSF5, tumor necrosis factor (ligand) superfamily member 5, IMD3, HIGM1
- [C07K 16/2875](#) - CD178, CD95L, CD95-L, CD95 ligand, FasL, Fas-L, Fas ligand, Apo-1L, Apo-1 ligand, APT1LG1, TNFSF6, tumor necrosis factor (ligand) superfamily member 6
- [C07K 16/2875](#) - CD252, CD134L, CD134-L, CD134 ligand, gp34, OX40L, OX40-L, OX40 ligand, Act-4L, Act-4-L, Act-4 ligand, TXGP1, TNFSF4, TNFSF-4, tumor necrosis factor (ligand) superfamily member 4
- [C07K 16/2875](#) - CD253, AIM-I, apoptosis-inducing molecule I, AGP-1, Apo-2L, Apo-2 ligand, TL2, TRAIL, TNFSF10, TNFSF-10, tumor necrosis factor (ligand) superfamily member 10, TL-2
- [C07K 16/2875](#) - CD254, RANKL, RANK-L, RANK ligand, OPGL, OPG-L, OPG ligand, osteoprotegerin ligand, osteoprotegerin binding protein, ODF, sODF, osteoclast differentiation factor, TRANCE, hRANKL2, TNFSF11, TNFSF-11,

DATE: JANUARY 1, 2026

PROJECT RP12806

- tumor necrosis factor (ligand) superfamily member 11, receptor activator of NF-kappa B ligand, receptor activator of NF-kB ligand
- [C07K 16/2875](#) - CD255, Apo-3L, Apo-3 ligand, TRELL, TRAIL-related ligand, TREPA, TNF-related endothelial proliferative agent, TWEAK, T cell ligand weakly inducing apoptosis, DR3L, TNFSF12, tumor necrosis factor (ligand) superfamily member 12
 - [C07K 16/2875](#) - CD256, APRIL, a proliferation-inducing ligand, TNF-related death ligand, TRDL, TRDL-1, TL3, TL-3, TNF ligand 3, TNF gamma, VEGI, vascular endothelial cell growth inhibitor, TALL2, TALL-2, TNFSF13, TNFSF-13, tumor necrosis factor (ligand) superfamily member 13
 - [C07K 16/2875](#) - CD257, BAFF, B cell activation factor, BLyS, TALL1, TALL-1, THANK, ZTNF4, TNFSF20, delta BAFF, TNFSF13B, TNFSF-13B, tumor necrosis factor (ligand) superfamily member 13B, ntn-2, kay-ligand, neutrokin
 - [C07K 16/2875](#) - CD258, LTg, HVEM, LIGHT, TNFSF14, TNFSF-14, tumor necrosis factor (ligand) superfamily member 14, TL5, TL-5
 - [C07K 16/2875](#) - AIM-II, apoptosis-inducing molecule II
 - [C07K 16/2875](#) - EDA, EDA1, ectodysplasin (isoform) A1
 - [C07K 16/2875](#) - EDA2, ectodysplasin (isoform) A2
 - [C07K 16/2875](#) - TL1A, TL-1A, TNFSF15, tumor necrosis factor superfamily member 15
 - [C07K 16/2875](#) - ZTNF13
 - [C07K 16/2878](#) - NGFR/TNFR superfamily, NGF receptor/TNF receptor superfamily
 - [C07K 16/2878](#) - CD27, TNFRSF7, tumor necrosis factor receptor superfamily member 7, Tp55, S152, T14
 - [C07K 16/2878](#) - CD30, Ber-H2, Ki-1, D1S166E, TNFRSF8, tumor necrosis factor receptor superfamily member 8,
 - [C07K 16/2878](#) - CD40, TNFRSF5, tumor necrosis factor receptor superfamily member 5, p50, Bp50
 - [C07K 16/2878](#) - CD40-associated protein, CAP
 - [C07K 16/2878](#) - CD95, Apo-1, Fas, APT1, TNFRSF6, tumor necrosis factor receptor superfamily member 6, apoptosis antigen 1
 - [C07K 16/2878](#) - CD120, TNFR, TNF receptor, tumor necrosis factor receptor
 - [C07K 16/2878](#) - CD120a, 55 kD TNFR, TNFR-1, TNFR-I, TNF receptor 1, TNF receptor I, TNFAR, TNFR60, p55, TNFRSF1A, tumor necrosis factor receptor superfamily member 1A

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2878](#) - CD120b, 75 kD TNFR, TNFR-2, TNFR-II, TNF receptor 2, TNF receptor II, TNFBR, TNFR80, p75, TNFRSF1B, tumor necrosis factor receptor superfamily member 1B
- [C07K 16/2878](#) - CD134, Act-4, OX40, OX-40, Stan-40, ACT35, TXGP1L, TNFRSF4, tumor necrosis factor receptor superfamily member 4
- [C07K 16/2878](#) - CD137, CDw137, ILA, induced by lymphocyte activation, 4-1BB, TNFRSF9, tumor necrosis factor receptor superfamily member 9
- [C07K 16/2878](#) - CD260, LT beta R, lymphotoxin beta receptor, LT beta receptor, TNFRSF3, TNFRSF-3, tumor necrosis factor receptor superfamily member 3, TNFCR, TNF-R-III, TNFR2-RP
- [C07K 16/2878](#) - CD261, DR4, death receptor 4, death domain-containing receptor 4, TR1, TRAILR1, TRAIL-R1, TRAIL receptor 1, Apo-2, APO2, apoptosis antigen 2, TNFRSF10a, TNFRSF-10a, tumor necrosis factor receptor superfamily member 10a, MGC9365
- [C07K 16/2878](#) - CD262, DR5, death receptor 5, death domain-containing receptor 5, TR2 (?), TRAILR2, TRAIL-R2, TRAIL receptor 2, KILLER, TRICK2, TRICKB, ZTNFR9, TNFRSF10b, TNFRSF-10b, tumor necrosis factor receptor superfamily member 10b
- [C07K 16/2878](#) - CD263, TR5, TNFR-5, TNF receptor 5, TRAILR3, TRAIL-R3, TRAIL receptor 3, TRID, LIT, DCR1, TNFRSF10c, TNFRSF-10c, tumor necrosis factor receptor superfamily member 10c
- [C07K 16/2878](#) - CD264, TR4, TRAILR4, TRAIL-R4, TRAIL receptor 4, DCR2, TRUNDD, TNFRSF10d, TNFRSF-10d, tumor necrosis factor receptor superfamily member 10d
- [C07K 16/2878](#) - CD265, RANK, receptor activator of NF-kappa B, ODAR, osteoclast differentiation and activation receptor, TRANCER, TRANCE-R, TRANCE receptor, EOF, FEO, OFE, ODFR, PDB2, TNFRSF11a, TNFRSF-11a, tumor necrosis factor receptor superfamily member 11a, osteoclast differentiation factor receptor, receptor activator of NF-kB
- [C07K 16/2878](#) - CD266, TWEAKR, TWEAK-R, TWEAK receptor, FN14, TNFRSF12a, TNFRSF-12a, tumor necrosis factor receptor superfamily member 12a, FGF-inducible 14
- [C07K 16/2878](#) - CD267, TACI, transmembrane activator and CAML interactor, TNFRSF13b, TNFRSF-13b, tumor necrosis factor receptor superfamily member 13b
- [C07K 16/2878](#) - CD268, BAFFR, BAFF-R, BAFF receptor, TNFRSF13c, TNFRSF-13c, tumor necrosis factor receptor superfamily member 13c, TR13c

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2878](#) - CD269, BCMA, B cell maturation antigen, TNFRSF17, TNFRSF-17, tumor necrosis factor receptor superfamily 17, TNFRSF13B
- [C07K 16/2878](#) - CD271, NGFR, NGF-R, NGF receptor, nerve growth factor receptor, p75(NTR), TNFRSF16, TNFRSF-16, tumor necrosis factor receptor superfamily member 16
- [C07K 16/2878](#) - CD357, AITR, GITR, TNFRSF18, tumor necrosis factor receptor superfamily member 18
- [C07K 16/2878](#) - CD358, DR6, death (domain(-containing)) receptor 6, TR7, TRAIL-R7, TRAIL receptor 7, TNFRSF21, tumor necrosis factor receptor superfamily member 21
- [C07K 16/2878](#) - BR3
- [C07K 16/2878](#) - DcR3, TNFRSF6B, tumor necrosis factor receptor superfamily member 6B
- [C07K 16/2878](#) - DR3, death receptor 3, death domain-containing receptor 3, TR3, TRAIL-R3, TRAIL receptor 3, DDR3, TRAMP, WSL-1, LARD, Apo-3, APO3, apoptosis antigen 3, TNFRSF12, tumor necrosis factor receptor superfamily member 12, TNFRSF25
- [C07K 16/2878](#) - EDAR, TNFRSF27, EDA1 receptor, ectodysplasin A1 receptor, EDA1R
- [C07K 16/2878](#) - EDA2R, ectodysplasin A2 receptor, TNFRSF27, tumor necrosis factor receptor superfamily member 27
- [C07K 16/2878](#) - XEDAR (?), X-linked EDA1 receptor, X-linked EDAR
- [C07K 16/2878](#) - FLINT, OPG-3, osteoprotegerin 3
- [C07K 16/2878](#) - HVEM, herpes simplex virus entry mediator, TR2, ATAR, LIGHTR, LIGHT-R, LIGHT receptor, HveA, TNFRSF14, tumor necrosis factor receptor superfamily member 14
- [C07K 16/2878](#) - OPG, osteoprotegerin, OCIF, osteoclastogenesis inhibitory factor, TNFRSF11b, tumor necrosis factor receptor superfamily member 11B
- [C07K 16/2878](#) - TNF-BP-I, tumor necrosis factor binding protein I
- [C07K 16/2878](#) - TNF-BP-II, tumor necrosis factor binding protein II
- [C07K 16/2878](#) - TRADD, TNF receptor 1 associated death domain protein
- [C07K 16/2878](#) - TR6, TRAILR6, TRAIL-R6, TRAIL receptor 6
- [C07K 16/2878](#) - TR13, TRAILR13, TRAIL-R13, TRAIL receptor 13
- [C07K 16/2878](#) - TR14, TRAILR14, TRAIL-R14, TRAIL receptor 14
- [C07K 16/2878](#) - TROY
- [C07K 16/2878](#) - XEDAR
- [C07K 16/2881](#) - CD71, TfR, transferrin receptor, T9

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2884](#) - CD44, ECMR-III, ECMR-III, extracellular matrix receptor (type) III, gp85, Hermes, H-CAM, HUTCH-1, ppg-1, phagocytic glycoprotein 1, p85
- [C07K 16/2884](#) - CD44R, CD44v
- [C07K 16/2887](#) - CD20, B1, Bp35
- [C07K 16/289](#) - CD45, B220, LCA, leukocyte common antigen, T200
- [C07K 16/289](#) - CD45R
- [C07K 16/289](#) - CD45RA
- [C07K 16/289](#) - CD45RB
- [C07K 16/289](#) - CD45RC
- [C07K 16/289](#) - CD45RO
- [C07K 16/2893](#) - CD52, CDw52, CAMPATH-1
- [C07K 16/2896](#) - CD5, Leu1, Leu-1, Ly-1, Lyt-1 (mouse), T1
- [C07K 16/2896](#) - CD6, T12
- [C07K 16/2896](#) - CD9, MRP-1, p24, MIC3, TSPAN29, TSPAN-29
- [C07K 16/2896](#) - CD10, CALLA, common acute lymphoblastic leukemia antigen, enkephalinase, gp100, NEP, neutral endopeptidase (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD12, CDw12, p90-120
- [C07K 16/2896](#) - CD13, APN, aminopeptidase N, gp150 (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD14, LPS receptor, Mo2
- [C07K 16/2896](#) - CD15, Lewis X, Lex, Le-x, x-hapten, 3-FAL, lacto-N-fucopentaose III, SSEA-1, stage-specific embryonic antigen 1
- [C07K 16/2896](#) - CD15s, sialylated CD15, sialylated Lewis X, sialylated Lex, sialylated Le-x, SLex
- [C07K 16/2896](#) - CD15u, sulphated CD15, sulfated Lewis X, sulfated Lex
- [C07K 16/2896](#) - CD17, CDw17, lacCer, lactosyl ceramide, lactosylceramide
- [C07K 16/2896](#) - CD21, B2, CR2, C3d receptor, EBVR, EBV-R, EBV receptor
- [C07K 16/2896](#) - CD24, HAS, heat-stable antigen, M1/69-J11d, BA-1
- [C07K 16/2896](#) - CD26, ADA binding protein, DPPIV, DPP IV, dipeptidyl peptidase IV (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD34, gp105-120
- [C07K 16/2896](#) - CD35, CR1, C3bR, C3b receptor, C4bR, C4b receptor
- [C07K 16/2896](#) - CD36, gp88, OKM5, PASIV, (platelet) gpIIb, (platelet) gpIV
- [C07K 16/2896](#) - CD37, gp52-40
- [C07K 16/2896](#) - CD38, T10
- [C07K 16/2896](#) - CD39
- [C07K 16/2896](#) - CD42

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2896](#) - CD42a, (platelet) gpIX
- [C07K 16/2896](#) - CD42b, (platelet) gpIb alpha, (platelet) gpIb alpha, (platelet) gpIba
- [C07K 16/2896](#) - CD42c, (platelet) gpIb beta, (platelet) gpIb beta, (platelet) gpIbb
- [C07K 16/2896](#) - CD42d, (platelet) gpV
- [C07K 16/2896](#) - CD43, gpL115, leukosialin, leukocyte sialoglycoprotein, LSCP, sialophorin
- [C07K 16/2896](#) - CD46, MCP, membrane cofactor protein
- [C07K 16/2896](#) - CD47R, CDw149
- [C07K 16/2896](#) - CD53, OX-44 (rat)
- [C07K 16/2896](#) - CD55, DAF, decay accelerating factor
- [C07K 16/2896](#) - CD57, Leu7, Leu-7, HNK1, HNK-1
- [C07K 16/2896](#) - CD59, HRF20, H19, MACIF, membrane attack complex inhibition factor, MIRL, membrane inhibitor of reactive lysis, protectin, p18, p-18, 1F5, MAC inhibitor, MEM-43, MACIP, MIC11
- [C07K 16/2896](#) - CD63, gp55, LIMP, MLA1, ME491, PTLGP40, LAMP-3
- [C07K 16/2896](#) - CD65, CDw65, ceramide dodecasaccharide
- [C07K 16/2896](#) - CD65s, sialylated CD65, VIM-2, VIM2
- [C07K 16/2896](#) - CD68, gp110, macrosialin (mouse)
- [C07K 16/2896](#) - CD73, ecto 5' nucleotidase (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD75, CDw75, lactosamine
- [C07K 16/2896](#) - CD75s, alpha-2-6-sialylated lactosamine
- [C07K 16/2896](#) - CD76, CDw76
- [C07K 16/2896](#) - CD77, BLA, Burkitt's lymphoma antigen, CTH, Gb3, globo triaosylceramide, Pk blood group antigen
- [C07K 16/2896](#) - CD78, CDw78, Ba
- [C07K 16/2896](#) - CD81, TAPA-1, target for anti-proliferative antigen 1
- [C07K 16/2896](#) - CD82, C33, IA4, KAI1, R2, 4F9
- [C07K 16/2896](#) - CD84, CDw84
- [C07K 16/2896](#) - CD87, uPAR, uPA-R, uPA receptor, urinary plasminogen activator receptor, urokinase-type plasminogen activator receptor, urokinase plasminogen activator receptor, Mo3, PLAUR, URKR, monocyte activation antigen
- [C07K 16/2896](#) - CD88, C5aR, C5a-R, C5a receptor
- [C07K 16/2896](#) - CD91, alpha2M-R, alpha2 macroglobulin receptor
- [C07K 16/2896](#) - CD92, CDw92, p70, CHTL1

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2896](#) - CD93, C1QR1
- [C07K 16/2896](#) - CD97, BL-KDD/F12
- [C07K 16/2896](#) - CD98, FRP-1, RL-388 (mouse), 4F2
- [C07K 16/2896](#) - CD99, E2, MIC2
- [C07K 16/2896](#) - CD99R
- [C07K 16/2896](#) - CD105, endoglin
- [C07K 16/2896](#) - CD107
- [C07K 16/2896](#) - CD107a, LAMP-1, lysosome-associated membrane protein 1
- [C07K 16/2896](#) - CD107b, LAMP-2, lysosome-associated membrane protein 2
- [C07K 16/2896](#) - CD108, CDw108, JMH
- [C07K 16/2896](#) - CD109, 7D1, 8A3
- [C07K 16/2896](#) - CD133, AC133, prominin-1, prominin-like 1
- [C07K 16/2896](#) - CD136, CDw136, macrophage-stimulating protein receptor, MSPR, MSP-R, MSP receptor, RON
- [C07K 16/2896](#) - CD138, syndecan-1, SDC-1
- [C07K 16/2896](#) - CD139, B-031
- [C07K 16/2896](#) - CD143, angiotensin-converting enzyme, carboxycathepsin, dipeptidyl carboxypeptidase, kininase II, peptidyl dipeptidase A, ACE (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD144, VE-cadherin, cadherin 5
- [C07K 16/2896](#) - CD145, CDw145
- [C07K 16/2896](#) - CD148, DEP-1, HPTP-epsilon, p260, p260 phosphatase, HTPT-eta
- [C07K 16/2896](#) - CD149, CDw149, MEM-133
- [C07K 16/2896](#) - CD151, PETA-3
- [C07K 16/2896](#) - CD155, PVR, polio virus receptor
- [C07K 16/2896](#) - CD156, MADM, kuz, kuzbanian, HsT18717
- [C07K 16/2896](#) - CD156a, ADAM8, a disintegrin and metalloproteinase domain 8
- [C07K 16/2896](#) - CD156b, CDw156C, ADAM17, a disintegrin and metalloproteinase domain 17, TACE
- [C07K 16/2896](#) - CD156c, CDw156C, ADAM10, a disintegrin and metalloproteinase domain 10
- [C07K 16/2896](#) - CD157, BST-1, BST1, BP-3/IF-7 (murine), Mo5
- [C07K 16/2896](#) - CD162, PSGL1, PSGL-1, P-selectin ligand 1, TAIP, T cell apoptosis inducing protein
- [C07K 16/2896](#) - CD162R, PEN5

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2896](#) - CD163, GHI/61, M130
- [C07K 16/2896](#) - CD163L, CD163-L, CD163 ligand
- [C07K 16/2896](#) - CD164, MGC24, MGC-24
- [C07K 16/2896](#) - CD165, AD2, gp37
- [C07K 16/2896](#) - CD168, RHAMM
- [C07K 16/2896](#) - CD172a, SIRP alpha
- [C07K 16/2896](#) - CD174, Lewis Y, Ley, Le-Y
- [C07K 16/2896](#) - CD175, Tn
- [C07K 16/2896](#) - CD175s, sialyl-Tn
- [C07K 16/2896](#) - CD176, TF, Thomson Friedenreich
- [C07K 16/2896](#) - CD177, NB1
- [C07K 16/2896](#) - CD180, RP105, RP-105
- [C07K 16/2896](#) - CD201, EPCR, EPC-R
- [C07K 16/2896](#) - CD203c, nucleotide pyrophosphatase/phosphodiesterase 3, phosphodiesterase 1/nucleotide pyrophosphatase 3, NPP3, E-NPP3, B10, gp130RBt3-6, PDNP3, Pdnppo, ENpp1 (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD204, macrophage scavenger receptor, MSR, MS-R
- [C07K 16/2896](#) - CD208, DC-LAMP
- [C07K 16/2896](#) - CD224, GGT, gamma-glutamyl transferase (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD225, Leu13, Leu-13
- [C07K 16/2896](#) - CD228, melanotransferrin
- [C07K 16/2896](#) - CD231, A15, CCG-B7, MXS1, MXS-1, membrane component X chromosome surface marker 1, TALLA, T cell acute lymphoblastic leukemia-associated antigen, TM4SF2, TM4FS-2, transmembrane 4 superfamily member 2, TALLA-1
- [C07K 16/2896](#) - CD232, VESPR, VESP-R, VESP receptor
- [C07K 16/2896](#) - CD233, band 3, SLC4A1
- [C07K 16/2896](#) - CD234, DARC, Fy-glycoprotein, Duffy
- [C07K 16/2896](#) - CD235a, glycophorin A
- [C07K 16/2896](#) - CD235b, glycophorin B
- [C07K 16/2896](#) - CD235ab, glycophorin A/B
- [C07K 16/2896](#) - CD236, glycophorin C/D
- [C07K 16/2896](#) - CD236R, glycophorin C
- [C07K 16/2896](#) - CD238, Kell
- [C07K 16/2896](#) - CD239, B-CAM
- [C07K 16/2896](#) - CD240CE, Rh30CE

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2896](#) - CD240D, Rh30D
- [C07K 16/2896](#) - CD240DCE, Rh30D/CE cross reactive mAbs
- [C07K 16/2896](#) - CD241, RhAg, Rh50
- [C07K 16/2896](#) - CD243, MDR-1, P-glycoprotein, p170
- [C07K 16/2896](#) - CD245, p220/240
- [C07K 16/2896](#) - CD246, ALK, Ki-1, anaplastic lymphoma kinase (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD249, ENPEP, glutamyl aminopeptidase, aminopeptidase A, APA, gp160 (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD281, TLR1, TLR-1, toll-like receptor 1, TIL, rsc786, KIAA0012, DKFZp547I0610, DKFZp564I0682
- [C07K 16/2896](#) - CD282, TLR2, TLR-2, toll-like receptor 2, TIL4
- [C07K 16/2896](#) - CD283, TLR3, TLR-3, toll-like receptor 3
- [C07K 16/2896](#) - CD284, TLR4, TLR-4, toll-like receptor 4, TOLL, hToll
- [C07K 16/2896](#) - CD285, TLR5, Toll-like receptor 5, TIL3, Toll/interleukin-1 receptor like protein/antigen
- [C07K 16/2896](#) - CD286, TLR6, TLR-6, toll-like receptor 6
- [C07K 16/2896](#) - CD287, TLR7, TLR-7, toll-like receptor 7
- [C07K 16/2896](#) - CD288, TLR8, TLR-8, toll-like receptor 8
- [C07K 16/2896](#) - CD289, TLR9, TLR-9, toll-like receptor 9
- [C07K 16/2896](#) - CD290, TLR10, TLR-10, toll-like receptor 10
- [C07K 16/2896](#) - CD291, TLR11, TLR-11, toll-like receptor 11
- [C07K 16/2896](#) - CD294, GPR44, G-protein-coupled receptor 44, CRTH2, chemoattractant receptor-homologous molecule expressed on TH2 cells
- [C07K 16/2896](#) - CD296, ART1, ADP-ribosyltransferase 1, RT6 (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD297, ART4, Dombrook blood group, DOK1, DO (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD298, ATP1B3, ATPase Na⁺/K⁺ transporting beta3, ATPB-3, FLJ29027, sodium/potassium-dependent ATPase beta3, sodium/potassium-transporting ATPase beta-3 chain (also in [C07K 16/40](#))
- [C07K 16/2896](#) - CD311, EMR1, EGF-like module containing mucin-like hormone receptor-like 1
- [C07K 16/2896](#) - CD312, EMR2, EGF-like module containing mucin-like hormone receptor-like 2
- [C07K 16/2896](#) - CD313, EMR3, EGF-like module containing mucin-like hormone receptor-like 3

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/2896](#) - CD317, BST2, bone marrow stromal cell antigen 2, BST-2, HM1.24
- [C07K 16/2896](#) - CD318, CDCP1, CUB domain-containing protein 1, FLJ22969, MGC31813, SIMA135, TRASK, B345
- [C07K 16/2896](#) - CD320, 8D6A, 8D6, TCbIR, transcobalamin receptor
- [C07K 16/2896](#) - CD324, E-cadherin (epithelial), CDH1, cadherin 1 type 1, uvomorulin, cell-CAM 120/80, calcium-dependent adhesion protein (epithelial)
- [C07K 16/2896](#) - CD325, N-cadherin (neuronal), CDH2, cadherin 2 type 1, calcium-dependent adhesion protein (neuronal), NCAD
- [C07K 16/2896](#) - CD338, CDw338, ABCG2, ATP-binding cassette subfamily G (white) member 2, MRX, MXR, ABCP, BCRP, BMDP, MXR1, MXR-1, ABC15, breast cancer resistance protein, mitoxantrone resistance protein, BCRP1
- [C07K 16/2896](#) - CD339, JAG1, jagged 1, AGS, AHD, AWS, HJ1, JAGL1, jagged
- [C07K 16/2896](#) - CD344, Frizzled 4, FZD4, FZD-4
- [C07K 16/2896](#) - CD349, Frizzled 9, FZD9, FZD-9, Fz-9, hFz9, FzE6
- [C07K 16/2896](#) - CD350, Frizzled 10, FZD10, FZD-10, Fz-10, hFz10, FzE7
- [C07K 16/2896](#) - CD351, FCA/MR
- [C07K 16/2896](#) - CD355, CRTAM
- [C07K 16/2896](#) - CD361, EV12B
- [C07K 16/2896](#) - CD362, syndecan-2, SDC2, HFGR1
- [C07K 16/2896](#) - CD363, SIPR1, EDG-1, CHEDG1
- [C07K 16/30](#) - CD326, EpCAM, Ep-CAM, Ly74, TACSTD1, tumor-associated calcium signal transducer 1, 17-1A, CO17-1A, EGP40, GA733-2, KSA, ESA, EGP, M4S1, MIC18, TROP1, EGP-2, epithelial glycoprotein 2, EGP2
- [C07K 16/30](#) - Clusterin
- [C07K 16/30](#) - GPNMB, nmb, hematopoietic growth factor inducible neurokinin-1 protein, HGFIN, bone-related gene osteoactivin
- [C07K 16/30](#) - GPR49
- [C07K 16/30](#) - KIAA0659
- [C07K 16/30](#) - Labyrinthin, Lab
- [C07K 16/30](#) - MH15
- [C07K 16/30](#) - MN, CA IX, carbonic anhydrase IX, G-250, CA9 (also in [C07K 16/40](#))
- [C07K 16/30](#) - 4Ig-B7-H3 (also in [C07K 16/2827](#))
- [C07K 16/30](#) - MAGE-A
- [C07K 16/30](#) - MAGE-B

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/30](#) - MAGE-C
- [C07K 16/30](#) - MAGE-D, NRAGE
- [C07K 16/30](#) - MAGE-E
- [C07K 16/30](#) - MAGE-F
- [C07K 16/30](#) - MAGE-G
- [C07K 16/30](#) - MAGE-H
- [C07K 16/30](#) - MAGE-L
- [C07K 16/30](#) - aMAGE
- [C07K 16/30](#) - dMAGE
- [C07K 16/30](#) - melanotransferrin, p9
- [C07K 16/30](#) - Piwil2, piwi-like 2, PL2L
- [C07K 16/30](#) - POTE
- [C07K 16/30](#) - TROP2, TROP-2, EGP-1, EGP1, GA733, GA733-1, M1S1, epithelial glycoprotein 1, gastrointestinal tumor-associated antigen 1, tumor-associated calcium signal transducer 2, TACSTD2
- [C07K 16/30](#) - 5T4, 5T4AG, TPBG, M6P1, trophoblast glycoprotein
- [C07K 16/3007](#) - CD66e, CEA, carcinoembryonic antigen, CEACAM5, CEACAM-5, carcinoembryonic antigen-related cell adhesion molecule 5
- [C07K 16/3015](#) - TIMP-2, tissue inhibitor of metalloproteinase 2
- [C07K 16/3023](#) - FAM3D
- [C07K 16/303](#) - PaCa-Agl, 3C4-Ag
- [C07K 16/303](#) - glypican 3, GPC3
- [C07K 16/3053](#) - MCSP, melanoma chondroitin sulfate proteoglycan, HMW-MAA, high molecular weight melanoma-associated antigen
- [C07K 16/3053](#) - Melan-A, MART-1
- [C07K 16/3069](#) - DD3, PCA3
- [C07K 16/3069](#) - HPC2, human prostate cancer (predisposing gene) 2
- [C07K 16/3069](#) - protocadherin-PC, PTCH-PC
- [C07K 16/3069](#) - Piwil1, piwi-like 1
- [C07K 16/3069](#) - PSA, prostate-specific antigen, kallikrein 3, APS, KLK2A1, P-30 antigen, gamma seminoprotein, semenogelase, seminol
- [C07K 16/3069](#) - PSCA, prostate stem cell antigen
- [C07K 16/3069](#) - PSMA, prostate-specific membrane antigen, glutamate carboxypeptidase II, N-acetylated alpha-linked acidic dipeptidase 1
- [C07K 16/3069](#) - PS118, PS-118
- [C07K 16/3084](#) - gangliosides
- [C07K 16/3084](#) - CD60, CDw60

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/3084](#) - CD60a, GD3
- [C07K 16/3084](#) - CD60b, 9-O-acetal GD3
- [C07K 16/3084](#) - CD60c, 7-O-acetyl-GD3
- [C07K 16/3084](#) - GD1
- [C07K 16/3084](#) - GD2
- [C07K 16/3084](#) - GM1
- [C07K 16/3084](#) - GM2
- [C07K 16/3084](#) - GM3
- [C07K 16/3084](#) - SC104
- [C07K 16/3092](#) - CD146, A32, MUC18, MUC-18, mucin 18, Mel-CAM, S-endo, MCAM, melanoma cell adhesion molecule
- [C07K 16/3092](#) - CD227, DF3, EMA, episialin, H23, mucin 1, MUC1, MUC-1, PEM, PUM, epithelial membrane antigen, peanut-reactive urinary mucin, polymorphic epithelial mucin, MAM-6, PAS-O, NPG, CA27.29
- [C07K 16/3092](#) - CSAp, colon-specific antigen p mucin
- [C07K 16/3092](#) - MUC4
- [C07K 16/3092](#) - MUC12
- [C07K 16/3092](#) - MUC16, CA-125
- [C07K 16/3092](#) - PAM4, PAM-4
- [C07K 16/3092](#) - porimin
- [C07K 16/3092](#) - TAG-72, tumor-associated glycoprotein 72, CC49, B72.3
- [C07K 16/32](#) - CD340, Her2, Her-2, ErbB2, ErbB-2, Neu, p185Her2, p185Neu, p185erbB2
- [C07K 16/32](#) - Her3, Her-3, ErbB3, ErbB-3
- [C07K 16/32](#) - Her4, Her-4, ErbB4, ErbB-4, tyro2
- [C07K 16/32](#) - MG20, CCNDBP1, cyclin D-type binding protein 1
- [C07K 16/32](#) - p95, N-truncated Her2
- [C07K 16/32](#) - MG20, CCNDBP1, cyclin D-type binding protein 1
- [C07K 16/32](#) - p95, N-truncated Her2
- [C07K 16/34](#) - Blood group antigen
- [C07K 16/34](#) - CD173, blood group H type 2
- [C07K 16/34](#) - ABO antigens
- [C07K 16/34](#) - HPA antigens
- [C07K 16/36](#) - CD141, thrombomodulin
- [C07K 16/36](#) - CD142, blood coagulation factor III, thrombokin, TF, tissue factor protein, tissue thromboplastin
- [C07K 16/36](#) - Factor I, blood coagulation factor I, fibrinogen

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/36](#) - Factor II, blood coagulation factor II, prothrombin
- [C07K 16/36](#) - Factor III, blood coagulation factor III, tissue thromboplastin
- [C07K 16/36](#) - Factor IV, blood coagulation factor IV
- [C07K 16/36](#) - Factor V, blood coagulation factor V, proaccelerin
- [C07K 16/36](#) - Factor VII, blood coagulation factor VII, proconvertin
- [C07K 16/36](#) - Factor VIII, blood coagulation factor VIII, antihemophilic factor, AHF, antihemophilic factor A
- [C07K 16/36](#) - Factor IX, blood coagulation factor IX, antihemophilic factor B, Christmas factor
- [C07K 16/36](#) - Factor X, blood coagulation factor X, Stuart factor, Stuart-Prower factor
- [C07K 16/36](#) - Factor XI, blood coagulation factor XI, plasma thromboplastin antecedent, antihemophilic factor C
- [C07K 16/36](#) - Factor XII, blood coagulation factor XII, Hageman factor
- [C07K 16/36](#) - Factor XIII, blood coagulation factor XIII, fibrin-stabilising factor, FSF
- [C07K 16/36](#) - HMWK, high molecular weight kininogen, HMWK-kallikrein factor, Fitzgerald factor, Williams-Fitzgerald-Flaujeac factor,
- [C07K 16/36](#) - vWF, von Willebrand's factor
- [C07K 16/38](#) - Protease inhibitors
- [C07K 16/38](#) - Alpha-1 antitrypsin
- [C07K 16/38](#) - Antithrombin III
- [C07K 16/38](#) - Cystatins
- [C07K 16/38](#) - Cystatin 1, CST1, CST-1
- [C07K 16/38](#) - Cystatin 2, CST2, CST-2
- [C07K 16/38](#) - Cystatin 3, CST3, CST-3
- [C07K 16/38](#) - Cystatin 4, CST4, CST-4
- [C07K 16/38](#) - Cystatin 5, CST5, CST-5
- [C07K 16/38](#) - Cystatin 6, CST6, CST-6
- [C07K 16/38](#) - Cystatin 7, CST7, CST-7
- [C07K 16/38](#) - Cystatin 8, CST8, CST-8
- [C07K 16/38](#) - Cystatin 9, CST9, CST-9
- [C07K 16/38](#) - Cystatin 11, CST11, CST-11
- [C07K 16/38](#) - Cystatin A, CSTA, CST-A
- [C07K 16/38](#) - Cystatin B, CSTB, CST-B
- [C07K 16/38](#) - Cystatin C, CSTC, CST-C

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/38](#) - HE4, whey acidic protein (WAP) four-disulfide core domain 2, major epididymis-specific protein E4, epididymal secretory protein E4, putative proteinase inhibitor WAP5
- [C07K 16/38](#) - Megsin
- [C07K 16/38](#) - Ovomucoid
- [C07K 16/38](#) - Pancreatic secretory inhibitor
- [C07K 16/38](#) - Plasminogen activator inhibitors
- [C07K 16/38](#) - TFPI, tissue factor pathway inhibitor, LACI, lipoprotein-associated coagulation factor, EPI, extrinsic pathway inhibitor
- [C07K 16/40](#) - enzymes
- [C07K 16/40](#) - CD10, CALLA, common acute lymphoblastic leukemia antigen, enkephalinase, gp100, NEP, neutral endopeptidase (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD13, APN, aminopeptidase N, gp150 (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD26, ADA binding protein, DPPIV, DPP IV, dipeptidyl peptidase IV (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD143, angiotensin-converting enzyme, carboxypeptidase, dipeptidyl carboxypeptidase, kininase II, peptidyl dipeptidase A (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD203c, nucleotide pyrophosphatase/phosphodiesterase 3, phosphodiesterase 1/nucleotide pyrophosphatase 3, NPP3, E-NPP3, B10, gp130RBt3-6, PDNP3, Pdnpro (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD224, gamma-glutamyl transferase (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD246, anaplastic lymphoma kinase (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD249, ENPEP, glutamyl aminopeptidase, aminopeptidase A, APA, gp160 (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD296, ART1, ADP-ribosyltransferase 1, RT6 (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD297, ART4, Dombrock blood group, DOK1, DO (also in [C07K 16/2896](#))
- [C07K 16/40](#) - CD298, ATP1B3, ATPase Na⁺/K⁺ transporting beta3, ATPB-3, FLJ29027, sodium/potassium-dependent ATPase beta3, sodium/potassium-transporting ATPase beta-3 chain (also in [C07K 16/2896](#))
- [C07K 16/40](#) - ADAM10 (also in [C07K 16/2896](#))
- [C07K 16/40](#) - ADAM12, meltrin alpha
- [C07K 16/40](#) - ADAM19, meltrin beta
- [C07K 16/40](#) - AKR1C1
- [C07K 16/40](#) - Cath, cathepsin

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/40](#) - Cath-D, cathepsin D
- [C07K 16/40](#) - Ceruloplasmin
- [C07K 16/40](#) - COX2, COX-2, cyclooxygenase 2, prostaglandin H2 synthase
- [C07K 16/40](#) - FAP-alpha, fibroblast activating protein alpha, fibroblast activation factor, seprase
- [C07K 16/40](#) - GPBP, Goodpasture antigen-binding protein
- [C07K 16/40](#) - HGFA, hepatocyte growth factor activator
- [C07K 16/40](#) - HtrA, high temperature requirement A
- [C07K 16/40](#) - HtrA1, high temperature requirement A1
- [C07K 16/40](#) - HtrA2, high temperature requirement A2, Omi
- [C07K 16/40](#) - HtrA3, high temperature requirement A3
- [C07K 16/40](#) - HtrA3-L, high temperature requirement A3 long (isoform)
- [C07K 16/40](#) - HtrA3-S, high temperature requirement A3 short (isoform)
- [C07K 16/40](#) - HtrA4, high temperature requirement A4
- [C07K 16/40](#) - iNOS, inducible nitric oxide synthase, inducible NO synthase
- [C07K 16/40](#) - Kallikrein
- [C07K 16/40](#) - LOX, lysyl oxidase
- [C07K 16/40](#) - LOXL1, LOR-1, lysyloxidase-related protein 1, lysyloxidase-like protein 1
- [C07K 16/40](#) - LOXL2, LOR-2, lysyloxidase-related protein 2, lysyloxidase-like protein 2
- [C07K 16/40](#) - LOXL3, LOR-3, lysyloxidase-related protein 3, lysyloxidase-like protein 3
- [C07K 16/40](#) - LOXL4, LOR-4, lysyloxidase-related protein 4, lysyloxidase-like protein 4
- [C07K 16/40](#) - MASP1, MASP-1, MBL-associated serine protease 1
- [C07K 16/40](#) - MASP2, MASP-2, MBL-associated serine protease 2
- [C07K 16/40](#) - MASP3, MASP-3, MBL-associated serine protease 3
- [C07K 16/40](#) - Memapsin 2, BACE, BACE1, ASP-2, beta-secretase
- [C07K 16/40](#) - MN, CA IX, carbonic anhydrase IX, G-250, CA9 (also in [C07K 16/30](#))
- [C07K 16/40](#) - PCSK9, proprotein convertase subtilisin/kexin type 9, FH3, HCHOLA3, LDLCQ1, NARC-1, NARC1, PC9, PCS9
- [C07K 16/40](#) - Protein C
- [C07K 16/40](#) - Pyk-2
- [C07K 16/40](#) - Seladin-1, selective Alzheimer's disease indicator 1, DHCR24, 24-dehydrocholesterol reductase

DATE: JANUARY 1, 2026

PROJECT RP12806

- [C07K 16/40](#) - SLLP1, sperm-specific lysozyme-like protein 1, C19
- [C07K 16/40](#) - SLLP2, sperm-specific lysozyme-like protein 2, C23
- [C07K 16/40](#) - SLLP3, sperm-specific lysozyme-like protein 3, C24
- [C07K 16/40](#) - SLLP4, sperm-specific lysozyme-like protein 4
- [C07K 16/40](#) - SLLP5, sperm-specific lysozyme-like protein 5
- [C07K 16/40](#) - SLLP6, sperm-specific lysozyme-like protein 6
- [C07K 16/40](#) - YKL-40, chondrex, HCgp39, HC-gp39, human cartilage glycoprotein 39, breast regression protein 39, Brp39
- [C07K 16/44](#) - Haptens
- [C07K 16/44](#) - (Modified) amino acid residues
- [C07K 16/44](#) - Metals
- [C07K 16/44](#) - DNA, RNA

Replace: The existing Glossary of terms table with the following updated table.

Glossary of terms

In this place, the following terms or expressions are used with the meaning indicated:

valency	number of bonds formed between the antigen-binding molecule (e.g. an antibody or fragment thereof) and the target antigen
dAb, sdAb	single domain antibody
VHH, Nanobody®	single domain antibody derived from camelids, e.g. camels, llamas, dromedaries, characterised by an extended CDR3 loop
VNAR	single domain antibody derived from cartilaginous fishes, e.g. sharks, rays

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

3. REVISION CONCORDANCE LIST (RCL)

Type*	From CPC Symbol (existing)	To CPC Symbol(s)
D	C07K 16/1002	<administrative transfer to C07K 16/102>
D	C07K 16/1003	<administrative transfer to C07K 16/104>
D	C07K 16/1009	<administrative transfer to C07K 16/106>
D	C07K 16/1018	<administrative transfer to C07K 16/108>
D	C07K 16/1027	<administrative transfer to C07K 16/11>
D	C07K 16/1036	<administrative transfer to C07K 16/112>
D	C07K 16/1045	<administrative transfer to C07K 16/114>
D	C07K 16/1054	<administrative transfer to C07K 16/1143>
D	C07K 16/1063	<administrative transfer to C07K 16/1145>
D	C07K 16/1072	<administrative transfer to C07K 16/1147>
D	C07K 16/1081	<administrative transfer to C07K 16/116>
D	C07K 16/109	<administrative transfer to C07K 16/118>

* C = entries with modified file scope where reclassification of documents from the entries is involved; Q = new entries which are firstly populated with documents via administrative transfers from deleted (D) entries. Afterwards, the transferred documents into the Q entry will either stay or be moved to more appropriate entries, as determined by intellectual reclassification; D = deleted entries; F = frozen entries will be deleted once reclassification of documents from the entries is completed.

NOTES:

- Only C, D, F, and Q type entries are included in the table above.
- When multiple symbols are included in the “To” column, do not use ranges of symbols.
- For administrative transfer of documents, the following text should be used: “< administrative transfer to XX>”, “<administrative transfer to XX and YY simultaneously>”, or “<administrative transfer to XX, YY, ...and ZZ simultaneously>” when administrative transfer of the same documents is to more than one place.
- Administrative transfer to main trunk groups is assumed to be the source allocation type, unless otherwise indicated.
- Administrative transfer to 2000/Y series groups is assumed to be “additional information”.
- If needed, instructions for allocation type should be indicated within the angle brackets using the abbreviations “ADD” or “INV”: <administrative transfer to XX ADD>, <administrative transfer to XX INV>, or < administrative transfer to XX ADD, YY INV, ... and ZZ ADD simultaneously>.
- In certain situations, the “D” entries of 2000-series or Y-series groups may not require a destination (“To”) symbol, however it is required to specify “<no transfer>” in the “To” column for such cases.
- RCL is not needed for finalisation projects.

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

4. CHANGES TO THE CPC-TO-IPC CONCORDANCE LIST (CICL)

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
C07K 16/081	C07K 16/081	UPDATE
C07K 16/082	C07K 16/082	UPDATE
C07K 16/084	C07K 16/084	UPDATE
C07K 16/085	C07K 16/085	UPDATE
C07K 16/087	C07K 16/087	UPDATE
C07K 16/088	C07K 16/085	UPDATE
C07K 16/089	C07K 16/085	UPDATE
C07K 16/1002		DELETE
C07K 16/1003		DELETE
C07K 16/1009		DELETE
C07K 16/1018		DELETE
C07K 16/102	C07K 16/102	NEW
C07K 16/1027		DELETE
C07K 16/1036		DELETE
C07K 16/104	C07K 16/104	NEW
C07K 16/1045		DELETE
C07K 16/1054		DELETE
C07K 16/106	C07K 16/106	NEW
C07K 16/1063		DELETE
C07K 16/1072		DELETE
C07K 16/108	C07K 16/108	NEW
C07K 16/1081		DELETE
C07K 16/109		DELETE
C07K 16/11	C07K 16/11	NEW
C07K 16/112	C07K 16/112	NEW
C07K 16/114	C07K 16/114	NEW
C07K 16/1143	C07K 16/114	NEW
C07K 16/1145	C07K 16/114	NEW
C07K 16/1147	C07K 16/114	NEW
C07K 16/116	C07K 16/116	NEW
C07K 16/118	C07K 16/118	NEW
C07K 16/1203	C07K 16/1203	UPDATE
C07K 16/1207	C07K 16/1203	UPDATE
C07K 16/121	C07K 16/121	UPDATE
C07K 16/1214	C07K 16/1214	UPDATE
C07K 16/1217	C07K 16/1217	UPDATE
C07K 16/1218	C07K 16/1218	UPDATE
C07K 16/1221	C07K 16/1203	UPDATE
C07K 16/1225	C07K 16/1203	UPDATE
C07K 16/1228	C07K 16/1228	UPDATE
C07K 16/1232	C07K 16/1232	UPDATE

CPC NOTICE OF CHANGES 1844

DATE: JANUARY 1, 2026

PROJECT RP12806

<u>CPC</u>	<u>IPC</u>	<u>Action*</u>
C07K 16/1235	C07K 16/1235	UPDATE
C07K 16/1239	C07K 16/1203	UPDATE
C07K 16/1242	C07K 16/1203	UPDATE
C07K 16/1246	C07K 16/1246	UPDATE
C07K 16/125	C07K 16/1203	UPDATE
C07K 16/1253	C07K 16/1203	UPDATE
C07K 16/1257	C07K 16/1203	UPDATE
C07K 16/126	C07K 16/126	UPDATE
C07K 16/1264	C07K 16/1203	UPDATE
C07K 16/1267	C07K 16/1267	UPDATE
C07K 16/1271	C07K 16/1271	UPDATE
C07K 16/1275	C07K 16/1275	UPDATE
C07K 16/1278	C07K 16/1278	UPDATE
C07K 16/1282	C07K 16/1282	UPDATE
C07K 16/1285	C07K 16/1267	UPDATE
C07K 16/1289	C07K 16/1289	UPDATE
C07K 16/1292	C07K 16/1267	UPDATE
C07K 16/1296	C07K 16/1267	UPDATE

*Action column:

- For an (N) or (Q) entry, provide an IPC symbol and complete the Action column with “NEW.”
- For an existing CPC main trunk entry or indexing entry where the existing IPC symbol needs to be changed, provide an updated IPC symbol and complete the Action column with “UPDATED.”
- For a (D) CPC entry or indexing entry complete the Action column with “DELETE.” IPC symbol does not need to be included in the IPC column.
- For an (N) 2000 series CPC entry which is positioned within the main trunk scheme (breakdown code) provide an IPC symbol and complete the action column with “NEW”.
- For an (N) 2000 series CPC entry positioned at the end of the CPC scheme (orthogonal code), with no IPC equivalent, complete the IPC column with “CPCONLY” and complete the action column with “NEW”.

NOTES:

- F symbols are not included in the CICAL table above.
- T and M symbols are not included in the CICAL table above unless a change to the existing IPC is desired.